<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_MCPRO100693 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEgr4 jpg ?>
<?FILEga1 jpg ?>
<?FILEmmc1 xlsx ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Mol Cell Proteomics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Mol Cell Proteomics</journal-id>
    <journal-title-group>
      <journal-title>Molecular &amp; Cellular Proteomics : MCP</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1535-9476</issn>
    <issn pub-type="epub">1535-9484</issn>
    <publisher>
      <publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10828474</article-id>
    <article-id pub-id-type="pii">S1535-9476(23)00204-9</article-id>
    <article-id pub-id-type="doi">10.1016/j.mcpro.2023.100693</article-id>
    <article-id pub-id-type="publisher-id">100693</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Technological Innovation and Resources</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>iProPhos: A Web-Based Interactive Platform for Integrated Proteome and Phosphoproteome Analysis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au1">
        <name>
          <surname>Zou</surname>
          <given-names>Jing</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="au2">
        <name>
          <surname>Qin</surname>
          <given-names>Ziran</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="au3">
        <name>
          <surname>Li</surname>
          <given-names>Ran</given-names>
        </name>
        <email>ranli1993@zju.edu.cn</email>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="fn1" ref-type="fn">‡</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <contrib contrib-type="author" id="au4">
        <name>
          <surname>Yan</surname>
          <given-names>Xiaohua</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author" id="au5">
        <name>
          <surname>Huang</surname>
          <given-names>Huizhe</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author" id="au6">
        <name>
          <surname>Yang</surname>
          <given-names>Bing</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author" id="au7">
        <name>
          <surname>Zhou</surname>
          <given-names>Fangfang</given-names>
        </name>
        <email>zhoufangfang@suda.edu.cn</email>
        <xref rid="aff6" ref-type="aff">6</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <contrib contrib-type="author" id="au8">
        <name>
          <surname>Zhang</surname>
          <given-names>Long</given-names>
        </name>
        <email>L_Zhang@zju.edu.cn</email>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff7" ref-type="aff">7</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <aff id="aff1"><label>1</label>The Second Affiliated Hospital and Life Sciences Institute and School of Medicine, The MOE Key Laboratory of Biosystems Homeostasis and Protection and Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Zhejiang University, Hangzhou, China</aff>
      <aff id="aff2"><label>2</label>School of Medicine, Hangzhou City University, Hangzhou, China</aff>
      <aff id="aff3"><label>3</label>Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang, China</aff>
      <aff id="aff4"><label>4</label>The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China</aff>
      <aff id="aff5"><label>5</label>Department of Pharmaceutical Chemistry and the Cardiovascular Research Institute, University of California, San Francisco, California, USA</aff>
      <aff id="aff6"><label>6</label>Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China</aff>
      <aff id="aff7"><label>7</label>Cancer Center, Zhejiang University, Hangzhou, China</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>∗</label>For correspondence: Ran Li; Fangfang Zhou; Long Zhang <email>ranli1993@zju.edu.cn</email><email>zhoufangfang@suda.edu.cn</email><email>L_Zhang@zju.edu.cn</email></corresp>
      <fn id="fn1">
        <label>‡</label>
        <p id="ntpara0010">These authors contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>12</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>12</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <volume>23</volume>
    <issue>1</issue>
    <elocation-id>100693</elocation-id>
    <history>
      <date date-type="received">
        <day>15</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>6</day>
        <month>11</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Authors</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="abs0010">
      <p>Large-scale omics studies have generated a wealth of mass spectrometry–based proteomics data, which provide additional insights into disease biology spanning genomic boundaries. However, there is a notable lack of web-based analysis and visualization tools that facilitate the reutilization of these data. Given this challenge, we present iProPhos, a user-friendly web server to deliver interactive and customizable functionalities. iProPhos incorporates a large number of samples, including 1444 tumor samples and 746 normal samples across 12 cancer types, sourced from the Clinical Proteomic Tumor Analysis Consortium. Additionally, users can also upload their own proteomics/phosphoproteomics data for analysis and visualization. In iProPhos, users can perform profiling plotting and differential expression, patient survival, clinical feature–related, and correlation analyses, including protein–protein, mRNA-protein, and kinase-substrate correlations. Furthermore, functional enrichment, protein–protein interaction network, and kinase-substrate enrichment analyses are accessible. iProPhos displays the analytical results in interactive figures and tables with various selectable parameters. It is freely accessible at <ext-link ext-link-type="uri" xlink:href="http://longlab-zju.cn/iProPhos" id="intref0010">http://longlab-zju.cn/iProPhos</ext-link> without login requirement. We present two case studies to demonstrate that iProPhos can identify potential drug targets and upstream kinases contributing to site-specific phosphorylation. Ultimately, iProPhos allows end-users to leverage the value of big data in cancer proteomics more effectively and accelerates the discovery of novel therapeutic targets.</p>
    </abstract>
    <abstract abstract-type="graphical" id="abs0015">
      <title>Graphical Abstract</title>
      <fig id="undfig1" position="anchor">
        <graphic xlink:href="ga1"/>
      </fig>
    </abstract>
    <abstract abstract-type="author-highlights" id="abs0020">
      <title>Highlights</title>
      <p>
        <list list-type="simple" id="ulist0010">
          <list-item id="u0010">
            <label>•</label>
            <p id="p0010">iProPhos performs integrated proteome and phosphoproteome analysis.</p>
          </list-item>
          <list-item id="u0020">
            <label>•</label>
            <p id="p0020">iProPhos provides optional parameters for plotting and statistical analysis.</p>
          </list-item>
          <list-item id="u0025">
            <label>•</label>
            <p id="p0025">iProPhos allows users to upload their own data for analysis and visualization.</p>
          </list-item>
          <list-item id="u0030">
            <label>•</label>
            <p id="p0030">iProPhos can identify potential drug targets and crucial phosphorylation events.</p>
          </list-item>
        </list>
      </p>
    </abstract>
    <abstract abstract-type="teaser" id="abs0025">
      <title>In Brief</title>
      <p>We have developed iProPhos, a user-friendly web server for integrated proteome and phosphoproteome analysis using CPTAC data for 12 cancer types. iProPhos has the capability of hosting abundant analyses such as differential expression, patient survival, clinical feature–related, kinase-substrate enrichment, and correlation analyses, including protein–protein, mRNA-protein, and kinase-substrate correlations. In addition, iProPhos provides functional enrichment and PPI network analyses. We present two case studies to demonstrate that iProPhos can identify potential drug targets and upstream kinases contributing to site-specific phosphorylation.</p>
    </abstract>
    <kwd-group id="kwrds0010">
      <title>Keywords</title>
      <kwd>proteomics</kwd>
      <kwd>phosphoproteomics</kwd>
      <kwd>integrated analysis</kwd>
      <kwd>web server</kwd>
      <kwd>tumor</kwd>
    </kwd-group>
  </article-meta>
  <def-list>
    <title>Abbreviations</title>
    <def-item>
      <term id="kwrd0035">BH</term>
      <def>
        <p>Benjamini–Hochberg</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0045">CPTAC</term>
      <def>
        <p>Clinical Proteomic Tumor Analysis Consortium</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0055">GSEA</term>
      <def>
        <p>gene set enrichment analysis</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0065">HCC</term>
      <def>
        <p>hepatocellular carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0075">KSEA</term>
      <def>
        <p>kinase-substrate enrichment analysis</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0085">PPI</term>
      <def>
        <p>protein–protein interaction</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0095">PTM</term>
      <def>
        <p>posttranslational modification</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0105">TMT</term>
      <def>
        <p>tandem mass tag</p>
      </def>
    </def-item>
  </def-list>
</front>
<body>
  <p id="p0035">Proteins execute various biological processes and carry biological information not accessible through genomics or transcriptomics (<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>). Protein phosphorylation is one of the most common and essential posttranslational modifications (PTMs) in biological systems, considerably affecting protein function, stability, and interactions with other cellular components (<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>). Weak or negative correlations between mRNA and protein abundance in certain genes hinder gene function predictions using transcriptomic data (<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>). With advancements in high-throughput technologies, MS-based proteomics has become a powerful tool in functional research (<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>). Large consortium projects, such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), have generated a tremendous amount of proteomic data. However, analyzing and mining these data require proficient programming skills, making proteomics analysis and visualization a considerable challenge for experimental and clinical personnel.</p>
  <p id="p0040">To date, several tools have been developed for proteomics analysis, including TCPA (<xref rid="bib12" ref-type="bibr">12</xref>), CPPA (<xref rid="bib13" ref-type="bibr">13</xref>), UALCAN (<xref rid="bib14" ref-type="bibr">14</xref>) and LinkedOmics (<xref rid="bib15" ref-type="bibr">15</xref>), but they offer a limited range of analytical types. TCPA is a web-based resource for accessing, analyzing, and visualizing cancer functional proteomics. However, it only encompasses approximately 300 reverse phase protein array–based protein markers and lacks normal samples for differential expression analysis. CPPA is an interactive web server for mining the characteristics of proteins and protein phosphorylation, but it cannot perform integrated analysis between proteomics and phosphoproteomics data. UALCAN and LinkedOmics are designed for the integrative analysis of multiomics data. However, UALCAN can only conduct differential expression analysis for proteomics data, while LinkedOmics focuses on exploring associations between different types of attributes, and lacks the capability to identify differentially expressed proteins in tumors and perform functional enrichment analysis for them. Furthermore, TCPA, CPPA, and UALCAN do not support functional enrichment analysis and cannot evaluate the correlation between mRNA and protein abundance. None of these tools provide kinase-substrate correlation analysis or protein–protein interaction (PPI) network analysis. More importantly, none of them allow users to upload their own proteomics/phosphoproteomics data for analysis, and customized options for analyzing and visualizing data are limited.</p>
  <p id="p0045">To address the issues with the current proteomics data analysis tools, we have developed iProPhos, a user-friendly web server for integrated proteome and phosphoproteome analysis using CPTAC data for 12 cancer types, comprising 1444 tumor samples and 746 normal samples (<xref rid="appsec1" ref-type="sec">supplemental Table S1</xref>). Furthermore, iProPhos allows users to upload their preprocessed proteomics/phosphoproteomics data for analysis and visualization. iProPhos has “Proteome Analysis” and “Phosphoproteome Analysis” modules (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). These modules perform similar functions for differential analysis, survival analysis and clinical feature-related analyses (including age, gender, and tumor stage). In the “Proteome Analysis” module, iProPhos performs functional enrichment analysis on proteins of interest and incorporates transcriptomics data paired with proteomics data for each sample to conduct correlation analysis between mRNA and protein abundance. In the “Phosphoproteome Analysis” module, iProPhos can infer kinase activity changes in tumors and integrate proteomics and phosphoproteomics data for correlation analysis. Moreover, iProPhos allows users to customize the analytic parameters, graphic color, and point size. <xref rid="tbl1" ref-type="table">Table 1</xref> compares the key features of iProPhos with those of the other available tools. Overall, iProPhos overcomes the limitations of existing proteomics analysis tools by integrating proteomics with transcriptomics or phosphoproteomics, providing downstream functional enrichment analysis and PPI network analysis, as well as customized data visualization options. These distinguishing features considerably broaden the scope of applications of iProPhos.<fig id="fig1"><label>Fig. 1</label><caption><p><bold>Schematic of iProPhos.</bold> iProPhos collected the omics data from the CPTAC project. All datasets were uniformly processed with a standardized workflow. iProPhos also allows users to upload their preprocessed data for analysis. iProPhos has analysis modules including “Proteome Analysis” and “Phosphoproteome Analysis,” as well as their integrated analysis. The <italic>bottom part</italic> shows the representative outputs of each module. iProPhos allows users to customize graphic parameters and statistical methods. CPTAC, Clinical Proteomic Tumor Analysis Consortium; FC, fold change; GSEA, gene set enrichment analysis; ORA, over-representation analysis; PPI, protein–protein interaction.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Comparison of iProPhos with existing web servers</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Feature</th><th>TCPA</th><th>CPPA</th><th>UALCN</th><th>LinkedOmics</th><th>iProPhos</th></tr></thead><tbody><tr><td>Data type</td><td>RPPA- based</td><td>MS-based</td><td>MS-based</td><td>RPPA- and MS-based</td><td>MS-based</td></tr><tr><td>Differential expression analysis</td><td>-</td><td>√</td><td>√</td><td>-</td><td>√</td></tr><tr><td>Functional enrichment analysis</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>PPI network analysis</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>mRNA-protein correlation</td><td>-</td><td>-</td><td>-</td><td>√</td><td>√</td></tr><tr><td>Survival analysis</td><td>√</td><td>√</td><td>-</td><td>√</td><td>√</td></tr><tr><td>Kinase-substrate correlation</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>Clinical features–related analysis</td><td>√</td><td>√</td><td>-</td><td>√</td><td>√</td></tr><tr><td>User upload</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>Customized options</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Symbols used for feature evaluations with “√” for present, “-”for absent. The URLs for each tool are given below.</p></fn><fn id="tspara0020"><p>TCPA: <ext-link ext-link-type="uri" xlink:href="https://www.tcpaportal.org/tcpa/" id="intref0045">https://www.tcpaportal.org/tcpa/</ext-link>.</p></fn><fn id="tspara0025"><p>CPPA: <ext-link ext-link-type="uri" xlink:href="http://cppa.site/cppa/" id="intref0050">http://cppa.site/cppa/</ext-link>.</p></fn><fn id="tspara0030"><p>UALCAN: <ext-link ext-link-type="uri" xlink:href="https://ualcan.path.uab.edu/" id="intref0055">https://ualcan.path.uab.edu/</ext-link>.</p></fn><fn id="tspara0035"><p>LinkedOmics: <ext-link ext-link-type="uri" xlink:href="http://linkedomics.org/" id="intref0060">http://linkedomics.org/</ext-link>.</p></fn><fn id="tspara0040"><p>iProPhos: <ext-link ext-link-type="uri" xlink:href="http://longlab-zju.cn/iProPhos/" id="intref0065">http://longlab-zju.cn/iProPhos/</ext-link>.</p></fn><fn id="tspara0045"><p>Abbreviations: MS, mass spectrometry; RPPA, reverse phase protein array.</p></fn></table-wrap-foot></table-wrap></p>
  <p id="p0050">To test iProPhos and demonstrate its capabilities, we presented two case studies and showed that iProPhos had good performance in investigating potential drug targets and revealing crucial phosphosites and their upstream kinases. In summary, iProPhos can provide new insights into the mechanisms underlying cancer progression and facilitate the exploration of novel therapeutic strategies for researchers.</p>
  <sec id="sec1">
    <title>Experimental Procedures</title>
    <sec id="sec1.1">
      <title>Data Collection</title>
      <p id="p0055">Transcriptome, proteome, phosphoproteome, and clinical characteristic data of 12 cancer types were sourced from the CPTAC data portal (<ext-link ext-link-type="uri" xlink:href="https://proteomic.datacommons.cancer.gov/pdc/" id="intref0015">https://proteomic.datacommons.cancer.gov/pdc/</ext-link>) (<xref rid="bib16" ref-type="bibr">16</xref>). The expression levels of the transcripts were quantified using the normalized metric, FPKM-UQ (<ext-link ext-link-type="uri" xlink:href="https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/Expression_mRNA_Pipeline/" id="intref0020">https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/Expression_mRNA_Pipeline/</ext-link>). Protein abundance and phosphorylation levels were uniformly processed using the common data analysis pipeline (<xref rid="bib17" ref-type="bibr">17</xref>). Clinical characteristics included age, gender, tumor stage, survival status, and survival time. In addition, we collected proteomics and phosphoproteomics data from matched normal samples, as well as transcriptomics data paired with proteomics data from tumor samples.</p>
    </sec>
    <sec id="sec1.2">
      <title>Data Preprocessing</title>
      <p id="p0060">For the transcriptomics data, we centered and scaled the normalized gene expression data to generate standardized expression values (z-scores). In the proteomics data, we filtered proteins with more than 50% missing values across samples and imputed missing values using KNN algorithm implemented in the R package impute. The principles of the filter and imputation method for missing values were also applied to the phosphoproteomics data. Proteomics and phosphoproteomics data were tandem mass tag–based, and the relative abundances of proteins or phosphosites are presented as log2 tandem mass tag ratios with the median centering.</p>
    </sec>
    <sec id="sec1.3">
      <title>Implementation</title>
      <p id="p0065">The iProPhos web server is freely available to all users without login requirement for access. We built it on the R Shiny framework, using the HTML5, CSS, and Shiny JavaScript (shinyjs) libraries for rendering and interactive operations of front-end pages. The user interface layout is organized with a sidebar containing widgets for target inputs and options for analysis and visualization. The main panel displays the outputs in plot or table formats. Interactive tables were generated using the R package DT (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/DT/index.html" id="PC_linkjU1sp757lb">https://cran.r-project.org/web/packages/DT/index.html</ext-link>) to facilitate efficient data querying and selection. All outputs are available for download, with plots saved in PDF format as editable vector graphics compatible with vector graphic editors, such as Adobe Illustrator. iProPhos has been successfully tested on several browsers, including Google Chrome, Firefox, Internet Explorer (version 10 or later), and Safari. The R packages used in the web server are listed in <xref rid="appsec1" ref-type="sec">supplemental Table S2</xref>.</p>
    </sec>
  </sec>
  <sec id="sec2">
    <title>Results</title>
    <sec id="sec2.1">
      <title>iProPhos Performs Proteomics-Related Analyses</title>
      <p id="p0070">iProPhos can perform proteomics-related analyses and integrates transcriptomics data to investigate the complex relationships between gene expression and protein abundance in biological systems.</p>
      <p id="p0075">Differentially expressed proteins between tumor and normal samples drive tumorigenesis and progression. iProPhos conducts differential expression analysis using two approaches and presents the results with box plots and volcano plots (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>A</italic>). For the box plots, users can choose <italic>t</italic> test, Wilcoxon test, or ANOVA methods for hypothesis testing to evaluate the differences between two groups of samples. The <italic>t</italic> test is two-tailed and assumes unequal variances, and the Wilcoxon test is a Wilcoxon rank-sum test. The box color and point size are customizable. For the volcano plots, iProPhos fits a linear model to calculate the fold change and statistical significance of proteins using the R package limma (<xref rid="bib18" ref-type="bibr">18</xref>). Users can also set the cutoff value to define significance. Upregulated and downregulated proteins in tumor samples are labeled orange and blue respectively, whereas gray indicates nonsignificance. Moreover, a protein of interest can be magnified and highlighted with its gene symbol. The interactive table is displayed under a volcano plot containing the fold change and statistical significance data.<fig id="fig2"><label>Fig. 2</label><caption><p><bold>Proteome analysis module of iProPhos.</bold><italic>A</italic>, iProPhos presents differential expression analysis results with <italic>boxplots</italic> or <italic>volcano plots</italic>. <italic>B</italic>, the <italic>scatter plot</italic> illustrates the correlation between the abundance of two interested proteins, and the table displays the correlation of the abundance of one interested protein with the other detectable proteins in a given tumor type. <italic>C</italic>, Kaplan–Meier curves for overall survival. Patients are grouped based on the abundance of the protein of interest. <italic>D</italic>, iProPhos provides correlation analysis between mRNA and protein abundance. <italic>E</italic>–<italic>G</italic>, iProPhos provides clinical feature–related analysis for protein abundance, including age (<italic>E</italic>), gender (<italic>F</italic>), and tumor stage (<italic>G</italic>). <italic>H</italic>, iProPhos presents gene ontology (GO) enrichment analysis results with <italic>bar plots</italic> or <italic>dot plots</italic>. <italic>I</italic>, iProPhos presents Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analysis results with <italic>bar plots</italic> or <italic>dot plots</italic>. <italic>J</italic>, iProPhos can perform GSEA analysis for the target gene set. <italic>K</italic>, the PPI network map of proteins of interest. BP, biological process; CC, cell component; GSEA, gene set enrichment analysis; MF, molecular function; PPI, protein–protein interaction.</p></caption><graphic xlink:href="gr2"/></fig></p>
      <p id="p0080">Correlation analysis is essential for evaluating cooperative relationships between any two proteins. iProPhos delivers correlation results in the form of scatter plots or tables (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>B</italic>), allowing users to explore protein correlations conveniently. In the “Correlation Plot” tab panel, users can investigate correlations between two proteins of interest in a specific tumor and customize various graphic parameters (such as point size and color) and correlation measuring methods (<italic>e.g.</italic>, Pearson, Spearman, and Kendall correlations). In the “Correlation Table” tab panel, users can investigate correlations of the target protein with other proteins to gain biological ideas for further study.</p>
      <p id="p0085">Survival analysis can associate protein abundance with clinical outcomes and provide valuable insights for selecting potential drug targets. iProPhos provides two methods for calculating the cut-off value that divides patients into two groups. One method is to set the median value of protein abundance as the cutoff point, and the other is to utilize the surv_cutpoint algorithm applied in the R package survminer to determine the optimal cut-off point. The colors for these two groups are also customizable. iProPhos outputs Kaplan–Meier survival curves with log-rank <italic>p</italic> values and 95% confidence intervals (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>C</italic>).</p>
      <p id="p0090">Proteins are functionally relevant to phenotypes. However, the extent to which protein abundance correlates with the mRNA level and whether this correlation breaks down in some genes are not fully understood. mRNA-protein correlation analysis can refine our understanding of the principles of gene expression control in tumor cells (<xref rid="bib19" ref-type="bibr">19</xref>). iProPhos can perform correlation analysis between given mRNA and protein in the specific cancer type (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>D</italic>). The point size, color, and analysis methods are customizable.</p>
      <p id="p0095">iProPhos can investigate associations between protein abundance and clinical features, such as age, gender, and tumor stage (<xref rid="fig2" ref-type="fig">Fig. 2</xref>, <italic>E</italic>–<italic>G</italic>), which are crucial for identifying potential prognostic biomarkers and advancing personalized medicine. For age-relevant analysis, iProPhos allows users to choose the patients’ median age or to input a suitable number as the cutoff value. These analyses output the results with violin plots. The methods for differential analysis are optional, except for tumor stage-related analysis, where one-way ANOVA is required.</p>
      <p id="p0100">Enrichment analysis focuses on gene sets that share common biological attributes, helping researchers identify dysregulated pathways and generate hypothesises (<xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>). iProPhos performs over-representation analysis and gene set enrichment analysis (GSEA) using the R package clusterProfiler (<xref rid="bib22" ref-type="bibr">22</xref>). For over-representation analysis analysis, users can set a cut-off value to define differentially upregulated or downregulated proteins. Then functional enrichment analysis is performed based on Gene Ontology (<xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>) or Kyoto Encyclopedia of Genes and Genomes (<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>) annotations. Redundant Gene Ontology terms are removed using “simplify” method to present the most informative terms. The results are output in the table format and displayed with bar plots and dot plots (<xref rid="fig2" ref-type="fig">Fig. 2, H and I</xref>). For GSEA analysis, users can input the gene list of interest and rank genes based on the fold change from the differential expression analysis. The GSEA result is shown graphically, along with statistical significance (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>J</italic>).</p>
      <p id="p0105">PPI networks represent the relationships between proteins that are crucial for deciphering the mechanisms of cellular processes and diseases. iProPhos performs PPI network analysis using the R package stringdb (<xref rid="bib27" ref-type="bibr">27</xref>). Users can customize the cut-off value to define proteins for network analysis. iProPhos also generates an interactive network diagram of protein interactions (including both physical and functional interactions) (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>K</italic>). Nodes represent proteins, and edges represent their interactions, with thicker edges indicating a higher confidence of interactions. Additionally, users can download the results in tabular format for further analysis in Cytoscape (<ext-link ext-link-type="uri" xlink:href="https://cytoscape.org/" id="PC_linkGCNF8L3jHq">https://cytoscape.org/</ext-link>) or other similar software.</p>
    </sec>
    <sec id="sec2.2">
      <title>iProPhos Performs Phosphoproteomics-Related Analyses</title>
      <p id="p0110">iProPhos can perform phosphoproteomics-related analyses and integrate with proteomics data, gaining insights into the aberrant phosphorylation events associated with tumorigenesis and progression. The clinical feature-related analysis for phosphorylation level, including age, gender, and tumor stage (<xref rid="fig3" ref-type="fig">Fig. 3</xref>, <italic>A</italic>–<italic>C</italic>), and differential analysis comparing phosphorylation level of phosphosites between tumor and normal samples (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>D</italic>), are the same as those in the “Proteome Analysis” module. Therefore, these features are not repeated here.<fig id="fig3"><label>Fig. 3</label><caption><p><bold>Phosphoproteome analysis module of iProPhos.</bold><italic>A</italic>–<italic>C</italic>, iProPhos provides clinical feature–related analysis for phosphorylation level, including age (<italic>A</italic>), gender (<italic>B</italic>), and tumor stage (<italic>C</italic>). <italic>D</italic>, iProPhos presents differential phosphorylation level analysis results with <italic>boxplots</italic> or <italic>volcano plots</italic>. <italic>E</italic>, iProPhos provides correlation analysis between protein abundance and the phosphorylation level of the specific phosphosite. <italic>F</italic>, iProPhos conducts correlation analysis between protein abundance of kinases and phosphorylation levels of substrates. <italic>G</italic>, iProPhos estimates the changes in kinase activities in tumor samples compared to normal samples. The <italic>bar pl</italic>ot shows the normalized score for each kinase (z-score), weighted by the number of identified substrates. <italic>Red</italic> means significant activation in tumors, <italic>blue</italic> represents significant inactivation, and <italic>black</italic> denotes kinases with nonsignificant scores; the kinase scores table lists enrichment scores of all kinases; kinase-substrate links table shows the kinase and substrate relationships collected from the selected dataset. <italic>H</italic>, iProPhos performs overall survival analysis based on the phosphorylation level. The table shows the survival analysis results for all detected phosphosites of a given protein; Kaplan–Meier curves show the survival analysis result for a certain phosphosite. The statistical significance is determined by log-rank test.</p></caption><graphic xlink:href="gr3"/></fig></p>
      <p id="p0115">Studying the correlation between protein abundance and the phosphorylation levels of phosphosites provides new insights into the regulatory networks and mechanisms driving tumor progression. iProPhos can evaluate the correlation not only between proteins and their phosphosites but also between proteins and phosphosites on different proteins (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>E</italic>).</p>
      <p id="p0120">The abundance of some kinases correlates with their known substrate phosphorylation levels (<italic>e.g.</italic>, CDK1, CDK2) (<xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>). iProPhos can investigate correlations between the protein abundance of kinases and the phosphorylation levels of substrates. The results are presented with the table consisting of kinase-substrate links and the corresponding correlation coefficient and <italic>p</italic> value (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>F</italic>). These analyses can provide potential kinase-substrate pairs and reveal the complexity of signaling pathways and networks. The kinase list was collected from PhosphoSitePlus (<xref rid="bib30" ref-type="bibr">30</xref>) (<ext-link ext-link-type="uri" xlink:href="http://www.phosphosite.org" id="intref0025">http://www.phosphosite.org</ext-link>), a well-established resource containing expert-curated annotations, and NetworKIN (<xref rid="bib31" ref-type="bibr">31</xref>) (<ext-link ext-link-type="uri" xlink:href="https://networkin.info/" id="intref0030">https://networkin.info/</ext-link>), which consists of predicted kinase-substrate relationships obtained by integrating various data sources, including sequence-based predictions, experimental kinase-substrate relationships, and PPI networks.</p>
      <p id="p0125">iProPhos can estimate changes in kinase activity based on collective phosphorylation changes of identified substrates using the kinase-substrate enrichment analysis (KSEA) algorithm (<xref rid="bib32" ref-type="bibr">32</xref>). Differential phosphorylation analysis is performed between tumor and normal samples for a given tumor type using the R package limma, and the results are analyzed using the KSEA module. Users can choose the data sources of the kinase-substrate relationship. Among them, PhosphoSitePlus includes only experimentally verified kinase-substrate relationships, which is recommended for more conservative results. In contrast, NetworKIN provides the predicted relationships. iProPhos presents the results with graphic and tabular formats (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>G</italic>). The kinase scores are displayed with bar plots; kinases labeled red are predicted to be significantly activated in tumors, kinases labeled blue are predicted to be significantly inactivated, and black indicates nonsignificance. The list of kinase scores provides the enrichment scores of kinases with at least one identified substrate in the selected dataset, and the list of kinase-substrate links provides the kinase-substrate relationships collected from the selected dataset.</p>
      <p id="p0130">Exploring the correlation between phosphorylation levels and clinical outcomes is valuable for further studies. iProPhos generates a convenient table that provides survival analysis results for all detected phosphosites in a given protein (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>H</italic>). Using this function, users can easily select phosphosites that significantly correlate with survival outcomes. iProPhos provides the Kaplan–Meier survival curve plot using the log-rank test (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>H</italic>). The grouping methods and colors are customizable.</p>
    </sec>
    <sec id="sec2.3">
      <title>iProPhos can Identify Potential Drug Targets</title>
      <p id="p0135">Proteomics data provide an excellent opportunity to identify candidate proteins for future clinical treatments, potentially leading to beneficial outcomes. iProPhos has the ability to screen candidate targets. Take the instance of pancreatic ductal adenocarcinoma, which is a highly aggressive malignancy with the low survival rate (<xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>). First, we conducted differential expression analysis between tumor and normal samples using the limma algorithm based on protein abundance. To control the false discovery rate, we used Benjamini–Hochberg (BH) correction for all proteins and the same correction applies to all results in this article. Second, the Food and Drug Administration approved or candidate drug targets were extracted from the Human Protein Atlas. Overlapping proteins between drug targets and differentially expressed proteins (BH adjusted <italic>p</italic> &lt; 0.05) were selected for further analysis. Then, we focused on two proteins, PIEZO1 and PLAU, which were significantly upregulated in tumors (<xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>A</italic> and <italic>B</italic>). PIEZO1 is a mechanosensitive ion channel, which transduces various mechanical stimulations into electrochemical signals (<xref rid="bib35" ref-type="bibr">35</xref>), and PLAU is a serine protease, which promotes fibrinolysis and degradation of extracellular matrix (<xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>). In addition, we also employed the Wilcoxon test to validate the differences in protein abundance (PIEZO1, BH adjusted <italic>p</italic> = 1.3e-04; PLAU, BH adjusted <italic>p</italic> = 1.6e-22; <xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>C</italic> and <italic>D</italic>). Furthermore, we performed survival analysis to investigate the possibility of these two proteins as drug targets. Based on the optimal cut-off point, we classified patients into high- and low-expression groups and found a significant survival difference between them. The high-expression group exhibited a poorer survival outcome than the low-expression group (log-rank test, BH adjusted <italic>p</italic> = 0.027, and BH adjusted <italic>p</italic> = 0.014 for PIEZO1 and PLAU, respectively; <xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>E</italic> and <italic>F</italic>). Moreover, we found that PLAU genes exhibited significantly positive correlation between mRNA expression and its protein abundance, while PIEZO1 showed a weaker correlation (R = 0.75, BH adjusted <italic>p</italic> = 4.5e-24 for PLAU; R = 0.24, BH adjusted <italic>p</italic> = 7.7e-03 for PIEZO1; <xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>G</italic> and <italic>H</italic>). These findings highlight the importance of direct exploration of protein expression profiles, as relying solely on mRNA expression may overlook the critical information regarding protein regulation and function.<fig id="fig4"><label>Fig. 4</label><caption><p><bold>iProPhos could reveal potential drug targets and infer crucial phosphosites and their upstream kinases.</bold><italic>A</italic> and <italic>B</italic>, <italic>volcano plots</italic> show that PIEZO1 (<italic>A</italic>) and PLAU (<italic>B</italic>) are significantly upregulated in PDA (Benjamini–Hochberg [BH] adjusted <italic>p</italic> &lt; 0.05). <italic>C</italic> and <italic>D</italic>, PIEZO1 (<italic>C</italic>) and PLAU (<italic>D</italic>) show significantly higher expression in PDA. <italic>E</italic> and <italic>F</italic>, survival analysis of PDA patients based on the protein abundance of PIEZO1 (<italic>E</italic>) and PLAU (<italic>F</italic>). <italic>G</italic> and <italic>H</italic>, Pearson’s correlation analysis between mRNA and protein abundance of PIEZO1 (<italic>G</italic>) and PLAU (<italic>H</italic>). <italic>I</italic>, evaluation of kinase activity changes by kinase-substrate enrichment analysis in HCC. <italic>Red</italic> means significant activation in tumors, <italic>blue</italic> represents significant inactivation, and <italic>black</italic> denotes kinases with nonsignificant scores. <italic>J</italic>, Pearson’s correlation analysis between CDK1 abundance and the phosphorylation level of NCL-S67. <italic>K</italic>, <italic>boxplot</italic> shows that phosphorylation level of NCL-S67 is significantly upregulated in HCC. <italic>L</italic>, survival analysis of HCC patients based on the phosphorylation level of NCL-S67. HCC, hepatocellular carcinoma; PDA, pancreatic ductal adenocarcinoma.</p></caption><graphic xlink:href="gr4"/></fig></p>
      <p id="p0140">In summary, iProPhos is a valuable tool that enables researchers to conveniently explore cancer proteomics and identify potential drug targets.</p>
    </sec>
    <sec id="sec2.4">
      <title>iProPhos can Identify Crucial Phosphosites and Their Upstream Kinases</title>
      <p id="p0145">The identification of kinase-substrate relationships is crucial for understanding phosphorylation signals. Take the example of hepatocellular carcinoma (HCC), iProPhos inferred kinase activity changes using the KSEA method. Kinase-substrate annotations were obtained from PhosphoSitePlus and NetworKIN, and the NetworkKIN score cut-off was set to 8. Results showed a significant upregulation of the activity of CSNK2A1, CDK1, PLK1, PRKDC, and CDK2 in HCC (<xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>I</italic> and <xref rid="appsec1" ref-type="sec">supplemental Table S3</xref>). CDK1 plays a critical role in cell cycle progression, and the overactivation of CDK1 has been identified to be closely associated with tumorigenesis (<xref rid="bib38" ref-type="bibr">38</xref>). NCL-S67 was inferred to be the substrate of CDK1 (<xref rid="appsec1" ref-type="sec">supplemental Table S4</xref>). We further investigated the correlation between the protein abundance of CDK1 and the phosphorylation level of NCL-S67. The results demonstrated a significantly positive correlation between them (R = 0.81, BH adjusted <italic>p</italic> = 3.3e-25; <xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>J</italic>). We also found that the phosphorylation level of NCL-S67 was significantly upregulated in HCC compared with matched normal samples (Wilcoxon test, BH adjusted <italic>p</italic> = 2.1e-37; <xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>K</italic>). Next, we performed survival analysis using the median phosphorylation level of NCL-S67 as the cut-off value, finding that the high-expression group had a worse prognosis (log-rank test, BH adjusted <italic>p</italic> = 1.8e-03; <xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>L</italic>). These results demonstrate that iProPhos is a powerful tool for discovering critical phosphorylation events, which can ultimately improve our understanding of disease biology.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Discussion</title>
    <p id="p0150">Mass spectrometry–based proteomics is a widely effective method for identifying, characterizing, and quantifying proteins. Proteins play an indispensable role in biological processes, and PTMs of proteins can regulate the biological functions of cells. The presence of PTMs increases the chemical diversity and complexity of the proteins, making comprehensive analysis of proteomics crucial for understanding cancer biology. However, genomics and transcriptomics methods fail to capture information about PTMs, making proteomics the sole approach for large-scale study of these modifications.</p>
    <p id="p0155">In high-throughput proteomics, analyzing and interpreting quantitative results to propose biological or clinical hypotheses is an ongoing challenge. Currently, there is a scarcity of comprehensive analysis and visualization tools for proteomics data, particularly in phosphoproteomics. Therefore, we have developed iProPhos, a user-friendly web server that provides a comprehensive and integrated analysis platform for proteome and phosphoproteome data. iProPhos can not only separately explore proteomics/phosphoproteomics differences between sample groups, but also integrate proteomics with transcriptomics or phosphoproteomics. iProPhos has the competency of hosting more abundant analyses such as differential expression, patient survival, clinical feature-related, kinase-substrate enrichment, and correlation analyses, including protein–protein, mRNA-protein, and kinase-substrate correlations. In addition, iProPhos provides downstream functional enrichment analysis and PPI network analysis, enabling researchers to gain deeper insights into the functional implications and interactions of the proteins of interest. The extensive analyses provided by iProPhos, accessible with only a few clicks, enable researchers without programming skills to perform multiple analyses. Moreover, iProPhos provides a series of optional parameters for plotting and statistical analysis, helping generate publication-ready figures.</p>
    <p id="p0160">Most existing analysis tools focus on the transcriptome, but protein and mRNA levels exhibit discrepancies in certain genes (<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>). A previous study explored mRNA-protein correlations across 32 normal human tissues for each gene, finding that the median Spearman correlation was 0.46 (<xref rid="bib41" ref-type="bibr">41</xref>). It is suggested that proteomics data provide additional information missing in transcriptomic studies, facilitating a more comprehensive understanding of tumor development and the discovery of novel therapeutic strategies. Moreover, phosphoproteomics studies and their integrated analysis with proteomics data further enrich the breadth of the study, enabling the exploration of critical phosphorylation events and kinase-substrate relationships, which fill the gaps in a single-layer analysis and enhance our understanding of the molecular mechanisms underlying the disease.</p>
    <p id="p0165">Due to the limitation of available datasets integrating transcriptome, proteome, and phosphoproteome, iProPhos has collected omics data from only 12 cancer types. In the future, we will continue to incorporate more tumor proteomics datasets, including different cancer types. Moreover, we consider integrating proteomics data from various cancer cell lines in the next version, as these models provide valuable insights into understanding cellular processes and the underlying factors driving carcinogenesis. iProPhos currently provides correlation analysis for paired proteins, but it cannot identify biological networks based on pairwise correlations. In future iterations, iProPhos will provide weighted gene coexpression network analysis to find highly correlated protein clusters and identify hub proteins within those clusters. Furthermore, iProPhos will utilize advanced machine learning algorithms to enhance the efficiency and accuracy of biomarker identification. iProPho will be updated continuously and provide researchers with a powerful tool for studying the role of proteins and PTMs in tumor progression and further leveraging the value of big data in cancer proteomics.</p>
    <p id="p0170">In summary, iProPhos is an intuitive and time-saving tool for the cancer community to dissect oncogenic signaling networks and address unmet clinical needs. Its comprehensive analysis capabilities, integration of different omics data, and potential for biomarker identification make it a valuable asset to unravel the complexities of cancer biology and develop novel therapeutic interventions.</p>
  </sec>
  <sec sec-type="data-availability" id="sec4">
    <title>Data Availability</title>
    <p id="p0175">iProPhos is free and open to all users, with no login requirement. Transcriptome, proteome, phosphoproteome, and clinical data across 12 cancer types were sourced from the CPTAC data portal (<ext-link ext-link-type="uri" xlink:href="https://proteomic.datacommons.cancer.gov/pdc/" id="intref0035">https://proteomic.datacommons.cancer.gov/pdc/</ext-link>). The code for producing iProPhos will be deposited to GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/longLabzj/iProPhos/" id="intref0040">https://github.com/longLabzj/iProPhos/</ext-link>), and will be publicly available upon publication.</p>
  </sec>
  <sec sec-type="supplementary-material" id="sec5">
    <title>Supplemental Data</title>
    <p id="p0180">This article contains <xref rid="appsec1" ref-type="sec">supplemental data</xref>.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p id="p0185">The authors declare no competing interests.</p>
  </sec>
</body>
<back>
  <ref-list id="cebib0010">
    <title>References</title>
    <ref id="bib1">
      <label>1</label>
      <element-citation publication-type="journal" id="sref1">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>Yaffe</surname>
            <given-names>M.B.</given-names>
          </name>
        </person-group>
        <article-title>Protein regulation in signal transduction</article-title>
        <source>Cold Spring Harb. Perspect. Biol.</source>
        <volume>8</volume>
        <year>2016</year>
        <object-id pub-id-type="publisher-id">a005918</object-id>
      </element-citation>
    </ref>
    <ref id="bib2">
      <label>2</label>
      <element-citation publication-type="journal" id="sref2">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Tong</surname>
            <given-names>R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials</article-title>
        <source>Signal. Transduct. Target. Ther.</source>
        <volume>5</volume>
        <year>2020</year>
        <fpage>213</fpage>
        <pub-id pub-id-type="pmid">32968059</pub-id>
      </element-citation>
    </ref>
    <ref id="bib3">
      <label>3</label>
      <element-citation publication-type="journal" id="sref3">
        <person-group person-group-type="author">
          <name>
            <surname>Timp</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Timp</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>Beyond mass spectrometry, the next step in proteomics</article-title>
        <source>Sci. Adv.</source>
        <volume>6</volume>
        <year>2020</year>
        <object-id pub-id-type="publisher-id">eaax8978</object-id>
      </element-citation>
    </ref>
    <ref id="bib4">
      <label>4</label>
      <element-citation publication-type="journal" id="sref4">
        <person-group person-group-type="author">
          <name>
            <surname>Bilbrough</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Piemontese</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Seitz</surname>
            <given-names>O.</given-names>
          </name>
        </person-group>
        <article-title>Dissecting the role of protein phosphorylation: a chemical biology toolbox</article-title>
        <source>Chem. Soc. Rev.</source>
        <volume>51</volume>
        <year>2022</year>
        <fpage>5691</fpage>
        <lpage>5730</lpage>
        <pub-id pub-id-type="pmid">35726784</pub-id>
      </element-citation>
    </ref>
    <ref id="bib5">
      <label>5</label>
      <element-citation publication-type="journal" id="sref5">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>Z.H.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z.Y.</given-names>
          </name>
        </person-group>
        <article-title>Regulatory mechanisms and novel therapeutic targeting strategies for protein tyrosine phosphatases</article-title>
        <source>Chem. Rev.</source>
        <volume>118</volume>
        <year>2018</year>
        <fpage>1069</fpage>
        <lpage>1091</lpage>
        <pub-id pub-id-type="pmid">28541680</pub-id>
      </element-citation>
    </ref>
    <ref id="bib6">
      <label>6</label>
      <element-citation publication-type="journal" id="sref6">
        <person-group person-group-type="author">
          <name>
            <surname>Hunter</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling</article-title>
        <source>Cell</source>
        <volume>80</volume>
        <year>1995</year>
        <fpage>225</fpage>
        <lpage>236</lpage>
        <pub-id pub-id-type="pmid">7834742</pub-id>
      </element-citation>
    </ref>
    <ref id="bib7">
      <label>7</label>
      <element-citation publication-type="journal" id="sref7">
        <person-group person-group-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>E.C.B.</given-names>
          </name>
          <name>
            <surname>Carter</surname>
            <given-names>E.K.</given-names>
          </name>
          <name>
            <surname>Dammer</surname>
            <given-names>E.B.</given-names>
          </name>
          <name>
            <surname>Duong</surname>
            <given-names>D.M.</given-names>
          </name>
          <name>
            <surname>Gerasimov</surname>
            <given-names>E.S.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level</article-title>
        <source>Nat. Neurosci.</source>
        <volume>25</volume>
        <year>2022</year>
        <fpage>213</fpage>
        <lpage>225</lpage>
        <pub-id pub-id-type="pmid">35115731</pub-id>
      </element-citation>
    </ref>
    <ref id="bib8">
      <label>8</label>
      <element-citation publication-type="journal" id="sref8">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Beyer</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Aebersold</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>On the dependency of cellular protein levels on mRNA abundance</article-title>
        <source>Cell</source>
        <volume>165</volume>
        <year>2016</year>
        <fpage>535</fpage>
        <lpage>550</lpage>
        <pub-id pub-id-type="pmid">27104977</pub-id>
      </element-citation>
    </ref>
    <ref id="bib9">
      <label>9</label>
      <element-citation publication-type="journal" id="sref9">
        <person-group person-group-type="author">
          <name>
            <surname>Giudice</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Petsalaki</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>Proteomics and phosphoproteomics in precision medicine: applications and challenges</article-title>
        <source>Brief. Bioinform.</source>
        <volume>20</volume>
        <year>2019</year>
        <fpage>767</fpage>
        <lpage>777</lpage>
        <pub-id pub-id-type="pmid">29077858</pub-id>
      </element-citation>
    </ref>
    <ref id="bib10">
      <label>10</label>
      <element-citation publication-type="journal" id="sref10">
        <person-group person-group-type="author">
          <name>
            <surname>Aebersold</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Mann</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Mass spectrometry-based proteomics</article-title>
        <source>Nature</source>
        <volume>422</volume>
        <year>2003</year>
        <fpage>198</fpage>
        <lpage>207</lpage>
        <pub-id pub-id-type="pmid">12634793</pub-id>
      </element-citation>
    </ref>
    <ref id="bib11">
      <label>11</label>
      <element-citation publication-type="journal" id="sref11">
        <person-group person-group-type="author">
          <name>
            <surname>Meissner</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Geddes-McAlister</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mann</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bantscheff</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>The emerging role of mass spectrometry-based proteomics in drug discovery</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <volume>21</volume>
        <year>2022</year>
        <fpage>637</fpage>
        <lpage>654</lpage>
        <pub-id pub-id-type="pmid">35351998</pub-id>
      </element-citation>
    </ref>
    <ref id="bib12">
      <label>12</label>
      <element-citation publication-type="journal" id="sref12">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Akbani</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Ju</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Roebuck</surname>
            <given-names>P.L.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TCPA: a resource for cancer functional proteomics data</article-title>
        <source>Nat. Methods</source>
        <volume>10</volume>
        <year>2013</year>
        <fpage>1046</fpage>
        <lpage>1047</lpage>
      </element-citation>
    </ref>
    <ref id="bib13">
      <label>13</label>
      <element-citation publication-type="journal" id="sref13">
        <person-group person-group-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>G.S.</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>Z.Z.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>Y.H.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>D.C.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>CPPA: a web tool for exploring proteomic and phosphoproteomic data in cancer</article-title>
        <source>J. Proteome Res.</source>
        <volume>22</volume>
        <year>2023</year>
        <fpage>368</fpage>
        <lpage>373</lpage>
        <pub-id pub-id-type="pmid">36507870</pub-id>
      </element-citation>
    </ref>
    <ref id="bib14">
      <label>14</label>
      <element-citation publication-type="journal" id="sref14">
        <person-group person-group-type="author">
          <name>
            <surname>Chandrashekar</surname>
            <given-names>D.S.</given-names>
          </name>
          <name>
            <surname>Karthikeyan</surname>
            <given-names>S.K.</given-names>
          </name>
          <name>
            <surname>Korla</surname>
            <given-names>P.K.</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Shovon</surname>
            <given-names>A.R.</given-names>
          </name>
          <name>
            <surname>Athar</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>UALCAN: an update to the integrated cancer data analysis platform</article-title>
        <source>Neoplasia</source>
        <volume>25</volume>
        <year>2022</year>
        <fpage>18</fpage>
        <lpage>27</lpage>
        <pub-id pub-id-type="pmid">35078134</pub-id>
      </element-citation>
    </ref>
    <ref id="bib15">
      <label>15</label>
      <element-citation publication-type="journal" id="sref15">
        <person-group person-group-type="author">
          <name>
            <surname>Vasaikar</surname>
            <given-names>S.V.</given-names>
          </name>
          <name>
            <surname>Straub</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B.</given-names>
          </name>
        </person-group>
        <article-title>LinkedOmics: analyzing multi-omics data within and across 32 cancer types</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>46</volume>
        <year>2018</year>
        <fpage>D956</fpage>
        <lpage>D963</lpage>
        <pub-id pub-id-type="pmid">29136207</pub-id>
      </element-citation>
    </ref>
    <ref id="bib16">
      <label>16</label>
      <element-citation publication-type="journal" id="sref16">
        <person-group person-group-type="author">
          <name>
            <surname>Edwards</surname>
            <given-names>N.J.</given-names>
          </name>
          <name>
            <surname>Oberti</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Thangudu</surname>
            <given-names>R.R.</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>McGarvey</surname>
            <given-names>P.B.</given-names>
          </name>
          <name>
            <surname>Jacob</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The CPTAC data portal: a resource for cancer proteomics research</article-title>
        <source>J. Proteome Res.</source>
        <volume>14</volume>
        <year>2015</year>
        <fpage>2707</fpage>
        <lpage>2713</lpage>
        <pub-id pub-id-type="pmid">25873244</pub-id>
      </element-citation>
    </ref>
    <ref id="bib17">
      <label>17</label>
      <element-citation publication-type="journal" id="sref17">
        <person-group person-group-type="author">
          <name>
            <surname>Rudnick</surname>
            <given-names>P.A.</given-names>
          </name>
          <name>
            <surname>Markey</surname>
            <given-names>S.P.</given-names>
          </name>
          <name>
            <surname>Roth</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mirokhin</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Tchekhovskoi</surname>
            <given-names>D.V.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A description of the clinical proteomic tumor analysis consortium (CPTAC) common data analysis pipeline</article-title>
        <source>J. Proteome Res.</source>
        <volume>15</volume>
        <year>2016</year>
        <fpage>1023</fpage>
        <lpage>1032</lpage>
        <pub-id pub-id-type="pmid">26860878</pub-id>
      </element-citation>
    </ref>
    <ref id="bib18">
      <label>18</label>
      <element-citation publication-type="journal" id="sref18">
        <person-group person-group-type="author">
          <name>
            <surname>Ritchie</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Phipson</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Law</surname>
            <given-names>C.W.</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>43</volume>
        <year>2015</year>
        <fpage>e47</fpage>
        <pub-id pub-id-type="pmid">25605792</pub-id>
      </element-citation>
    </ref>
    <ref id="bib19">
      <label>19</label>
      <element-citation publication-type="journal" id="sref19">
        <person-group person-group-type="author">
          <name>
            <surname>Buccitelli</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Selbach</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>mRNAs, proteins and the emerging principles of gene expression control</article-title>
        <source>Nat. Rev. Genet.</source>
        <volume>21</volume>
        <year>2020</year>
        <fpage>630</fpage>
        <lpage>644</lpage>
        <pub-id pub-id-type="pmid">32709985</pub-id>
      </element-citation>
    </ref>
    <ref id="bib20">
      <label>20</label>
      <element-citation publication-type="journal" id="sref20">
        <person-group person-group-type="author">
          <name>
            <surname>Subramanian</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Tamayo</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Mootha</surname>
            <given-names>V.K.</given-names>
          </name>
          <name>
            <surname>Mukherjee</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ebert</surname>
            <given-names>B.L.</given-names>
          </name>
          <name>
            <surname>Gillette</surname>
            <given-names>M.A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>
        <source>Proc. Natl. Acad. Sci. U. S. A.</source>
        <volume>102</volume>
        <year>2005</year>
        <fpage>15545</fpage>
        <lpage>15550</lpage>
        <pub-id pub-id-type="pmid">16199517</pub-id>
      </element-citation>
    </ref>
    <ref id="bib21">
      <label>21</label>
      <element-citation publication-type="journal" id="sref21">
        <person-group person-group-type="author">
          <name>
            <surname>Tipney</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Hunter</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>An introduction to effective use of enrichment analysis software</article-title>
        <source>Hum. Genomics</source>
        <volume>4</volume>
        <year>2010</year>
        <fpage>202</fpage>
        <lpage>206</lpage>
        <pub-id pub-id-type="pmid">20368141</pub-id>
      </element-citation>
    </ref>
    <ref id="bib22">
      <label>22</label>
      <element-citation publication-type="journal" id="sref22">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>clusterProfiler 4.0: a universal enrichment tool for interpreting omics data</article-title>
        <source>Innovation (Camb.)</source>
        <volume>2</volume>
        <year>2021</year>
        <object-id pub-id-type="publisher-id">100141</object-id>
      </element-citation>
    </ref>
    <ref id="bib23">
      <label>23</label>
      <element-citation publication-type="journal" id="sref23">
        <person-group person-group-type="author">
          <name>
            <surname>Ashburner</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ball</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Blake</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Botstein</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Butler</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Cherry</surname>
            <given-names>J.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene ontology: tool for the unification of biology. The Gene Ontology Consortium</article-title>
        <source>Nat. Genet.</source>
        <volume>25</volume>
        <year>2000</year>
        <fpage>25</fpage>
        <lpage>29</lpage>
        <pub-id pub-id-type="pmid">10802651</pub-id>
      </element-citation>
    </ref>
    <ref id="bib24">
      <label>24</label>
      <element-citation publication-type="journal" id="sref24">
        <person-group person-group-type="author">
          <name>
            <surname>Gene Ontology</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>The gene ontology resource: enriching a GOld mine</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>49</volume>
        <year>2021</year>
        <fpage>D325</fpage>
        <lpage>D334</lpage>
        <pub-id pub-id-type="pmid">33290552</pub-id>
      </element-citation>
    </ref>
    <ref id="bib25">
      <label>25</label>
      <element-citation publication-type="journal" id="sref25">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Goto</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>28</volume>
        <year>2000</year>
        <fpage>27</fpage>
        <lpage>30</lpage>
        <pub-id pub-id-type="pmid">10592173</pub-id>
      </element-citation>
    </ref>
    <ref id="bib26">
      <label>26</label>
      <element-citation publication-type="journal" id="sref26">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Furumichi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Tanabe</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Morishima</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>45</volume>
        <year>2017</year>
        <fpage>D353</fpage>
        <lpage>D361</lpage>
        <pub-id pub-id-type="pmid">27899662</pub-id>
      </element-citation>
    </ref>
    <ref id="bib27">
      <label>27</label>
      <element-citation publication-type="journal" id="sref27">
        <person-group person-group-type="author">
          <name>
            <surname>Szklarczyk</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Gable</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Nastou</surname>
            <given-names>K.C.</given-names>
          </name>
          <name>
            <surname>Lyon</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Kirsch</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Pyysalo</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>49</volume>
        <year>2021</year>
        <fpage>D605</fpage>
        <lpage>D612</lpage>
        <pub-id pub-id-type="pmid">33237311</pub-id>
      </element-citation>
    </ref>
    <ref id="bib28">
      <label>28</label>
      <element-citation publication-type="journal" id="sref28">
        <person-group person-group-type="author">
          <name>
            <surname>Petralia</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Tignor</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Reva</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Koptyra</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Chowdhury</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Rykunov</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated proteogenomic characterization across major histological types of pediatric brain cancer</article-title>
        <source>Cell</source>
        <volume>183</volume>
        <year>2020</year>
        <fpage>1962</fpage>
        <lpage>1985.e31</lpage>
        <pub-id pub-id-type="pmid">33242424</pub-id>
      </element-citation>
    </ref>
    <ref id="bib29">
      <label>29</label>
      <element-citation publication-type="journal" id="sref29">
        <person-group person-group-type="author">
          <name>
            <surname>Arshad</surname>
            <given-names>O.A.</given-names>
          </name>
          <name>
            <surname>Danna</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Petyuk</surname>
            <given-names>V.A.</given-names>
          </name>
          <name>
            <surname>Piehowski</surname>
            <given-names>P.D.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Rodland</surname>
            <given-names>K.D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>An integrative analysis of tumor proteomic and phosphoproteomic profiles to examine the relationships between kinase activity and phosphorylation</article-title>
        <source>Mol. Cell. Proteomics</source>
        <volume>18</volume>
        <year>2019</year>
        <fpage>S26</fpage>
        <lpage>S36</lpage>
        <pub-id pub-id-type="pmid">31227600</pub-id>
      </element-citation>
    </ref>
    <ref id="bib30">
      <label>30</label>
      <element-citation publication-type="journal" id="sref30">
        <person-group person-group-type="author">
          <name>
            <surname>Hornbeck</surname>
            <given-names>P.V.</given-names>
          </name>
          <name>
            <surname>Kornhauser</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Tkachev</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Skrzypek</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>40</volume>
        <year>2012</year>
        <fpage>D261</fpage>
        <lpage>D270</lpage>
        <pub-id pub-id-type="pmid">22135298</pub-id>
      </element-citation>
    </ref>
    <ref id="bib31">
      <label>31</label>
      <element-citation publication-type="journal" id="sref31">
        <person-group person-group-type="author">
          <name>
            <surname>Linding</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>L.J.</given-names>
          </name>
          <name>
            <surname>Ostheimer</surname>
            <given-names>G.J.</given-names>
          </name>
          <name>
            <surname>van Vugt</surname>
            <given-names>M.A.T.M.</given-names>
          </name>
          <name>
            <surname>Jørgensen</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Miron</surname>
            <given-names>I.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Systematic discovery of in vivo phosphorylation networks</article-title>
        <source>Cell</source>
        <volume>129</volume>
        <year>2007</year>
        <fpage>1415</fpage>
        <lpage>1426</lpage>
        <pub-id pub-id-type="pmid">17570479</pub-id>
      </element-citation>
    </ref>
    <ref id="bib32">
      <label>32</label>
      <element-citation publication-type="journal" id="sref32">
        <person-group person-group-type="author">
          <name>
            <surname>Wiredja</surname>
            <given-names>D.D.</given-names>
          </name>
          <name>
            <surname>Koyuturk</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Chance</surname>
            <given-names>M.R.</given-names>
          </name>
        </person-group>
        <article-title>The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics</article-title>
        <source>Bioinformatics</source>
        <volume>33</volume>
        <year>2017</year>
        <fpage>3489</fpage>
        <lpage>3491</lpage>
        <pub-id pub-id-type="pmid">28655153</pub-id>
      </element-citation>
    </ref>
    <ref id="bib33">
      <label>33</label>
      <element-citation publication-type="journal" id="sref33">
        <person-group person-group-type="author">
          <name>
            <surname>Hutcheson</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Balaji</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Porembka</surname>
            <given-names>M.R.</given-names>
          </name>
          <name>
            <surname>Wachsmann</surname>
            <given-names>M.B.</given-names>
          </name>
          <name>
            <surname>McCue</surname>
            <given-names>P.A.</given-names>
          </name>
          <name>
            <surname>Knudsen</surname>
            <given-names>E.S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Immunologic and metabolic features of pancreatic ductal adenocarcinoma define prognostic subtypes of disease</article-title>
        <source>Clin. Cancer Res.</source>
        <volume>22</volume>
        <year>2016</year>
        <fpage>3606</fpage>
        <lpage>3617</lpage>
        <pub-id pub-id-type="pmid">26858311</pub-id>
      </element-citation>
    </ref>
    <ref id="bib34">
      <label>34</label>
      <element-citation publication-type="journal" id="sref34">
        <person-group person-group-type="author">
          <name>
            <surname>Payen</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Oberstein</surname>
            <given-names>P.E.</given-names>
          </name>
          <name>
            <surname>Saharkhiz</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Palermo</surname>
            <given-names>C.F.</given-names>
          </name>
          <name>
            <surname>Sastra</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Harmonic motion imaging of pancreatic tumor stiffness indicates disease state and treatment response</article-title>
        <source>Clin. Cancer Res.</source>
        <volume>26</volume>
        <year>2020</year>
        <fpage>1297</fpage>
        <lpage>1308</lpage>
        <pub-id pub-id-type="pmid">31831559</pub-id>
      </element-citation>
    </ref>
    <ref id="bib35">
      <label>35</label>
      <element-citation publication-type="journal" id="sref35">
        <person-group person-group-type="author">
          <name>
            <surname>Lai</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Cox</surname>
            <given-names>C.D.</given-names>
          </name>
          <name>
            <surname>Chandra Sekar</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Thurgood</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Jaworowski</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Peter</surname>
            <given-names>K.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mechanosensing by Piezo1 and its implications for physiology and various pathologies</article-title>
        <source>Biol. Rev. Camb. Philos. Soc.</source>
        <volume>97</volume>
        <year>2022</year>
        <fpage>604</fpage>
        <lpage>614</lpage>
        <pub-id pub-id-type="pmid">34781417</pub-id>
      </element-citation>
    </ref>
    <ref id="bib36">
      <label>36</label>
      <element-citation publication-type="journal" id="sref36">
        <person-group person-group-type="author">
          <name>
            <surname>Fang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Che</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lei</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF-kappaB/IL8 pathway</article-title>
        <source>Cell Death Discov.</source>
        <volume>7</volume>
        <year>2021</year>
        <fpage>32</fpage>
        <pub-id pub-id-type="pmid">33574243</pub-id>
      </element-citation>
    </ref>
    <ref id="bib37">
      <label>37</label>
      <element-citation publication-type="journal" id="sref37">
        <person-group person-group-type="author">
          <name>
            <surname>Sudol</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management</article-title>
        <source>Oncogene</source>
        <volume>30</volume>
        <year>2011</year>
        <fpage>3003</fpage>
        <lpage>3010</lpage>
        <pub-id pub-id-type="pmid">21383693</pub-id>
      </element-citation>
    </ref>
    <ref id="bib38">
      <label>38</label>
      <element-citation publication-type="journal" id="sref38">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Q.S.</given-names>
          </name>
          <name>
            <surname>Bode</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>T.S.</given-names>
          </name>
        </person-group>
        <article-title>Targeting CDK1 in cancer: mechanisms and implications</article-title>
        <source>NPJ Precis. Oncol.</source>
        <volume>7</volume>
        <year>2023</year>
        <fpage>58</fpage>
        <pub-id pub-id-type="pmid">37311884</pub-id>
      </element-citation>
    </ref>
    <ref id="bib39">
      <label>39</label>
      <element-citation publication-type="journal" id="sref39">
        <person-group person-group-type="author">
          <name>
            <surname>Fortelny</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Overall</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Pavlidis</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Freue</surname>
            <given-names>G.V.C.</given-names>
          </name>
        </person-group>
        <article-title>Can we predict protein from mRNA levels?</article-title>
        <source>Nature</source>
        <volume>547</volume>
        <year>2017</year>
        <fpage>E19</fpage>
        <lpage>E20</lpage>
        <pub-id pub-id-type="pmid">28748932</pub-id>
      </element-citation>
    </ref>
    <ref id="bib40">
      <label>40</label>
      <element-citation publication-type="journal" id="sref40">
        <person-group person-group-type="author">
          <name>
            <surname>Franks</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Airoldi</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Slavov</surname>
            <given-names>N.</given-names>
          </name>
        </person-group>
        <article-title>Post-transcriptional regulation across human tissues</article-title>
        <source>PLoS Comput. Biol.</source>
        <volume>13</volume>
        <year>2017</year>
        <object-id pub-id-type="publisher-id">e1005535</object-id>
      </element-citation>
    </ref>
    <ref id="bib41">
      <label>41</label>
      <element-citation publication-type="journal" id="sref41">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Jian</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A quantitative proteome map of the human body</article-title>
        <source>Cell</source>
        <volume>183</volume>
        <year>2020</year>
        <fpage>269</fpage>
        <lpage>283.e19</lpage>
        <pub-id pub-id-type="pmid">32916130</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="appsec1" sec-type="supplementary-material">
    <title>Supplemental Data</title>
    <p id="p0200">
      <supplementary-material content-type="local-data" id="mmc1">
        <caption>
          <title>Supplemental Tables S1–S4</title>
        </caption>
        <media xlink:href="mmc1.xlsx"/>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ack0010">
    <title>Acknowledgments</title>
    <p id="p0205">This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100012166</institution-id><institution>National Key R&amp;D Program of China</institution></institution-wrap></funding-source> (2021YFA1101000 and 2022YFA1105200), the <funding-source id="gs2">Chinese National Natural Science Funds</funding-source> (U20A20393, 32270975, 32070907, 92169122, 82371841, 32100699, 31771619, 32200575, and 22074132), the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100014219</institution-id><institution>National Science Fund for Distinguished Young Scholars</institution></institution-wrap></funding-source> (32125016 and 31925013), the <funding-source id="gs4">China National Postdoctoral Program for Innovative Talents</funding-source> (BX2021208), the <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source> (2021M692350) and <funding-source id="gs6">Suzhou Innovation and Entrepreneurship Leading Talent Program</funding-source> (ZXL2022505, ZXL2022442, and ZXL2023206), Key Cross-Research Projects of the School of Medicine, <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100022956</institution-id><institution>Soochow University</institution></institution-wrap></funding-source> (YXY2303027), and the <funding-source id="gs8">Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases</funding-source>. Additionally, we acknowledge the support from the <funding-source id="gs9">Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases</funding-source>，the platform of the <funding-source id="gs10">Zhejiang University School of Medicine</funding-source> and the <funding-source id="gs11">Life Sciences Institute</funding-source>.</p>
    <sec id="sec6">
      <title>Author contributions</title>
      <p id="p0195">J. Z., Z. Q., and R. L., methodology; J. Z. and Z. Q. writing-original draft; J. Z. software; Z. Q. visualization; X. Y., H. H., B. Y., F. Z., and L. Z. conceptualization; X. Y., H. H., F. Z., and L. Z. writing–review and editing.</p>
    </sec>
  </ack>
</back>
<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_MCPRO100693 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEgr4 jpg ?>
<?FILEga1 jpg ?>
<?FILEmmc1 xlsx ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Mol Cell Proteomics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Mol Cell Proteomics</journal-id>
    <journal-title-group>
      <journal-title>Molecular &amp; Cellular Proteomics : MCP</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1535-9476</issn>
    <issn pub-type="epub">1535-9484</issn>
    <publisher>
      <publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10828474</article-id>
    <article-id pub-id-type="pii">S1535-9476(23)00204-9</article-id>
    <article-id pub-id-type="doi">10.1016/j.mcpro.2023.100693</article-id>
    <article-id pub-id-type="publisher-id">100693</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Technological Innovation and Resources</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>iProPhos: A Web-Based Interactive Platform for Integrated Proteome and Phosphoproteome Analysis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au1">
        <name>
          <surname>Zou</surname>
          <given-names>Jing</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="au2">
        <name>
          <surname>Qin</surname>
          <given-names>Ziran</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="au3">
        <name>
          <surname>Li</surname>
          <given-names>Ran</given-names>
        </name>
        <email>ranli1993@zju.edu.cn</email>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="fn1" ref-type="fn">‡</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <contrib contrib-type="author" id="au4">
        <name>
          <surname>Yan</surname>
          <given-names>Xiaohua</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author" id="au5">
        <name>
          <surname>Huang</surname>
          <given-names>Huizhe</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author" id="au6">
        <name>
          <surname>Yang</surname>
          <given-names>Bing</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author" id="au7">
        <name>
          <surname>Zhou</surname>
          <given-names>Fangfang</given-names>
        </name>
        <email>zhoufangfang@suda.edu.cn</email>
        <xref rid="aff6" ref-type="aff">6</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <contrib contrib-type="author" id="au8">
        <name>
          <surname>Zhang</surname>
          <given-names>Long</given-names>
        </name>
        <email>L_Zhang@zju.edu.cn</email>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff7" ref-type="aff">7</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <aff id="aff1"><label>1</label>The Second Affiliated Hospital and Life Sciences Institute and School of Medicine, The MOE Key Laboratory of Biosystems Homeostasis and Protection and Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Zhejiang University, Hangzhou, China</aff>
      <aff id="aff2"><label>2</label>School of Medicine, Hangzhou City University, Hangzhou, China</aff>
      <aff id="aff3"><label>3</label>Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang, China</aff>
      <aff id="aff4"><label>4</label>The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China</aff>
      <aff id="aff5"><label>5</label>Department of Pharmaceutical Chemistry and the Cardiovascular Research Institute, University of California, San Francisco, California, USA</aff>
      <aff id="aff6"><label>6</label>Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China</aff>
      <aff id="aff7"><label>7</label>Cancer Center, Zhejiang University, Hangzhou, China</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>∗</label>For correspondence: Ran Li; Fangfang Zhou; Long Zhang <email>ranli1993@zju.edu.cn</email><email>zhoufangfang@suda.edu.cn</email><email>L_Zhang@zju.edu.cn</email></corresp>
      <fn id="fn1">
        <label>‡</label>
        <p id="ntpara0010">These authors contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>12</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>12</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <volume>23</volume>
    <issue>1</issue>
    <elocation-id>100693</elocation-id>
    <history>
      <date date-type="received">
        <day>15</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>6</day>
        <month>11</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Authors</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="abs0010">
      <p>Large-scale omics studies have generated a wealth of mass spectrometry–based proteomics data, which provide additional insights into disease biology spanning genomic boundaries. However, there is a notable lack of web-based analysis and visualization tools that facilitate the reutilization of these data. Given this challenge, we present iProPhos, a user-friendly web server to deliver interactive and customizable functionalities. iProPhos incorporates a large number of samples, including 1444 tumor samples and 746 normal samples across 12 cancer types, sourced from the Clinical Proteomic Tumor Analysis Consortium. Additionally, users can also upload their own proteomics/phosphoproteomics data for analysis and visualization. In iProPhos, users can perform profiling plotting and differential expression, patient survival, clinical feature–related, and correlation analyses, including protein–protein, mRNA-protein, and kinase-substrate correlations. Furthermore, functional enrichment, protein–protein interaction network, and kinase-substrate enrichment analyses are accessible. iProPhos displays the analytical results in interactive figures and tables with various selectable parameters. It is freely accessible at <ext-link ext-link-type="uri" xlink:href="http://longlab-zju.cn/iProPhos" id="intref0010">http://longlab-zju.cn/iProPhos</ext-link> without login requirement. We present two case studies to demonstrate that iProPhos can identify potential drug targets and upstream kinases contributing to site-specific phosphorylation. Ultimately, iProPhos allows end-users to leverage the value of big data in cancer proteomics more effectively and accelerates the discovery of novel therapeutic targets.</p>
    </abstract>
    <abstract abstract-type="graphical" id="abs0015">
      <title>Graphical Abstract</title>
      <fig id="undfig1" position="anchor">
        <graphic xlink:href="ga1"/>
      </fig>
    </abstract>
    <abstract abstract-type="author-highlights" id="abs0020">
      <title>Highlights</title>
      <p>
        <list list-type="simple" id="ulist0010">
          <list-item id="u0010">
            <label>•</label>
            <p id="p0010">iProPhos performs integrated proteome and phosphoproteome analysis.</p>
          </list-item>
          <list-item id="u0020">
            <label>•</label>
            <p id="p0020">iProPhos provides optional parameters for plotting and statistical analysis.</p>
          </list-item>
          <list-item id="u0025">
            <label>•</label>
            <p id="p0025">iProPhos allows users to upload their own data for analysis and visualization.</p>
          </list-item>
          <list-item id="u0030">
            <label>•</label>
            <p id="p0030">iProPhos can identify potential drug targets and crucial phosphorylation events.</p>
          </list-item>
        </list>
      </p>
    </abstract>
    <abstract abstract-type="teaser" id="abs0025">
      <title>In Brief</title>
      <p>We have developed iProPhos, a user-friendly web server for integrated proteome and phosphoproteome analysis using CPTAC data for 12 cancer types. iProPhos has the capability of hosting abundant analyses such as differential expression, patient survival, clinical feature–related, kinase-substrate enrichment, and correlation analyses, including protein–protein, mRNA-protein, and kinase-substrate correlations. In addition, iProPhos provides functional enrichment and PPI network analyses. We present two case studies to demonstrate that iProPhos can identify potential drug targets and upstream kinases contributing to site-specific phosphorylation.</p>
    </abstract>
    <kwd-group id="kwrds0010">
      <title>Keywords</title>
      <kwd>proteomics</kwd>
      <kwd>phosphoproteomics</kwd>
      <kwd>integrated analysis</kwd>
      <kwd>web server</kwd>
      <kwd>tumor</kwd>
    </kwd-group>
  </article-meta>
  <def-list>
    <title>Abbreviations</title>
    <def-item>
      <term id="kwrd0035">BH</term>
      <def>
        <p>Benjamini–Hochberg</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0045">CPTAC</term>
      <def>
        <p>Clinical Proteomic Tumor Analysis Consortium</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0055">GSEA</term>
      <def>
        <p>gene set enrichment analysis</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0065">HCC</term>
      <def>
        <p>hepatocellular carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0075">KSEA</term>
      <def>
        <p>kinase-substrate enrichment analysis</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0085">PPI</term>
      <def>
        <p>protein–protein interaction</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0095">PTM</term>
      <def>
        <p>posttranslational modification</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0105">TMT</term>
      <def>
        <p>tandem mass tag</p>
      </def>
    </def-item>
  </def-list>
</front>
<body>
  <p id="p0035">Proteins execute various biological processes and carry biological information not accessible through genomics or transcriptomics (<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>). Protein phosphorylation is one of the most common and essential posttranslational modifications (PTMs) in biological systems, considerably affecting protein function, stability, and interactions with other cellular components (<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>). Weak or negative correlations between mRNA and protein abundance in certain genes hinder gene function predictions using transcriptomic data (<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>). With advancements in high-throughput technologies, MS-based proteomics has become a powerful tool in functional research (<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>). Large consortium projects, such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), have generated a tremendous amount of proteomic data. However, analyzing and mining these data require proficient programming skills, making proteomics analysis and visualization a considerable challenge for experimental and clinical personnel.</p>
  <p id="p0040">To date, several tools have been developed for proteomics analysis, including TCPA (<xref rid="bib12" ref-type="bibr">12</xref>), CPPA (<xref rid="bib13" ref-type="bibr">13</xref>), UALCAN (<xref rid="bib14" ref-type="bibr">14</xref>) and LinkedOmics (<xref rid="bib15" ref-type="bibr">15</xref>), but they offer a limited range of analytical types. TCPA is a web-based resource for accessing, analyzing, and visualizing cancer functional proteomics. However, it only encompasses approximately 300 reverse phase protein array–based protein markers and lacks normal samples for differential expression analysis. CPPA is an interactive web server for mining the characteristics of proteins and protein phosphorylation, but it cannot perform integrated analysis between proteomics and phosphoproteomics data. UALCAN and LinkedOmics are designed for the integrative analysis of multiomics data. However, UALCAN can only conduct differential expression analysis for proteomics data, while LinkedOmics focuses on exploring associations between different types of attributes, and lacks the capability to identify differentially expressed proteins in tumors and perform functional enrichment analysis for them. Furthermore, TCPA, CPPA, and UALCAN do not support functional enrichment analysis and cannot evaluate the correlation between mRNA and protein abundance. None of these tools provide kinase-substrate correlation analysis or protein–protein interaction (PPI) network analysis. More importantly, none of them allow users to upload their own proteomics/phosphoproteomics data for analysis, and customized options for analyzing and visualizing data are limited.</p>
  <p id="p0045">To address the issues with the current proteomics data analysis tools, we have developed iProPhos, a user-friendly web server for integrated proteome and phosphoproteome analysis using CPTAC data for 12 cancer types, comprising 1444 tumor samples and 746 normal samples (<xref rid="appsec1" ref-type="sec">supplemental Table S1</xref>). Furthermore, iProPhos allows users to upload their preprocessed proteomics/phosphoproteomics data for analysis and visualization. iProPhos has “Proteome Analysis” and “Phosphoproteome Analysis” modules (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). These modules perform similar functions for differential analysis, survival analysis and clinical feature-related analyses (including age, gender, and tumor stage). In the “Proteome Analysis” module, iProPhos performs functional enrichment analysis on proteins of interest and incorporates transcriptomics data paired with proteomics data for each sample to conduct correlation analysis between mRNA and protein abundance. In the “Phosphoproteome Analysis” module, iProPhos can infer kinase activity changes in tumors and integrate proteomics and phosphoproteomics data for correlation analysis. Moreover, iProPhos allows users to customize the analytic parameters, graphic color, and point size. <xref rid="tbl1" ref-type="table">Table 1</xref> compares the key features of iProPhos with those of the other available tools. Overall, iProPhos overcomes the limitations of existing proteomics analysis tools by integrating proteomics with transcriptomics or phosphoproteomics, providing downstream functional enrichment analysis and PPI network analysis, as well as customized data visualization options. These distinguishing features considerably broaden the scope of applications of iProPhos.<fig id="fig1"><label>Fig. 1</label><caption><p><bold>Schematic of iProPhos.</bold> iProPhos collected the omics data from the CPTAC project. All datasets were uniformly processed with a standardized workflow. iProPhos also allows users to upload their preprocessed data for analysis. iProPhos has analysis modules including “Proteome Analysis” and “Phosphoproteome Analysis,” as well as their integrated analysis. The <italic>bottom part</italic> shows the representative outputs of each module. iProPhos allows users to customize graphic parameters and statistical methods. CPTAC, Clinical Proteomic Tumor Analysis Consortium; FC, fold change; GSEA, gene set enrichment analysis; ORA, over-representation analysis; PPI, protein–protein interaction.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Comparison of iProPhos with existing web servers</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Feature</th><th>TCPA</th><th>CPPA</th><th>UALCN</th><th>LinkedOmics</th><th>iProPhos</th></tr></thead><tbody><tr><td>Data type</td><td>RPPA- based</td><td>MS-based</td><td>MS-based</td><td>RPPA- and MS-based</td><td>MS-based</td></tr><tr><td>Differential expression analysis</td><td>-</td><td>√</td><td>√</td><td>-</td><td>√</td></tr><tr><td>Functional enrichment analysis</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>PPI network analysis</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>mRNA-protein correlation</td><td>-</td><td>-</td><td>-</td><td>√</td><td>√</td></tr><tr><td>Survival analysis</td><td>√</td><td>√</td><td>-</td><td>√</td><td>√</td></tr><tr><td>Kinase-substrate correlation</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>Clinical features–related analysis</td><td>√</td><td>√</td><td>-</td><td>√</td><td>√</td></tr><tr><td>User upload</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>Customized options</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Symbols used for feature evaluations with “√” for present, “-”for absent. The URLs for each tool are given below.</p></fn><fn id="tspara0020"><p>TCPA: <ext-link ext-link-type="uri" xlink:href="https://www.tcpaportal.org/tcpa/" id="intref0045">https://www.tcpaportal.org/tcpa/</ext-link>.</p></fn><fn id="tspara0025"><p>CPPA: <ext-link ext-link-type="uri" xlink:href="http://cppa.site/cppa/" id="intref0050">http://cppa.site/cppa/</ext-link>.</p></fn><fn id="tspara0030"><p>UALCAN: <ext-link ext-link-type="uri" xlink:href="https://ualcan.path.uab.edu/" id="intref0055">https://ualcan.path.uab.edu/</ext-link>.</p></fn><fn id="tspara0035"><p>LinkedOmics: <ext-link ext-link-type="uri" xlink:href="http://linkedomics.org/" id="intref0060">http://linkedomics.org/</ext-link>.</p></fn><fn id="tspara0040"><p>iProPhos: <ext-link ext-link-type="uri" xlink:href="http://longlab-zju.cn/iProPhos/" id="intref0065">http://longlab-zju.cn/iProPhos/</ext-link>.</p></fn><fn id="tspara0045"><p>Abbreviations: MS, mass spectrometry; RPPA, reverse phase protein array.</p></fn></table-wrap-foot></table-wrap></p>
  <p id="p0050">To test iProPhos and demonstrate its capabilities, we presented two case studies and showed that iProPhos had good performance in investigating potential drug targets and revealing crucial phosphosites and their upstream kinases. In summary, iProPhos can provide new insights into the mechanisms underlying cancer progression and facilitate the exploration of novel therapeutic strategies for researchers.</p>
  <sec id="sec1">
    <title>Experimental Procedures</title>
    <sec id="sec1.1">
      <title>Data Collection</title>
      <p id="p0055">Transcriptome, proteome, phosphoproteome, and clinical characteristic data of 12 cancer types were sourced from the CPTAC data portal (<ext-link ext-link-type="uri" xlink:href="https://proteomic.datacommons.cancer.gov/pdc/" id="intref0015">https://proteomic.datacommons.cancer.gov/pdc/</ext-link>) (<xref rid="bib16" ref-type="bibr">16</xref>). The expression levels of the transcripts were quantified using the normalized metric, FPKM-UQ (<ext-link ext-link-type="uri" xlink:href="https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/Expression_mRNA_Pipeline/" id="intref0020">https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/Expression_mRNA_Pipeline/</ext-link>). Protein abundance and phosphorylation levels were uniformly processed using the common data analysis pipeline (<xref rid="bib17" ref-type="bibr">17</xref>). Clinical characteristics included age, gender, tumor stage, survival status, and survival time. In addition, we collected proteomics and phosphoproteomics data from matched normal samples, as well as transcriptomics data paired with proteomics data from tumor samples.</p>
    </sec>
    <sec id="sec1.2">
      <title>Data Preprocessing</title>
      <p id="p0060">For the transcriptomics data, we centered and scaled the normalized gene expression data to generate standardized expression values (z-scores). In the proteomics data, we filtered proteins with more than 50% missing values across samples and imputed missing values using KNN algorithm implemented in the R package impute. The principles of the filter and imputation method for missing values were also applied to the phosphoproteomics data. Proteomics and phosphoproteomics data were tandem mass tag–based, and the relative abundances of proteins or phosphosites are presented as log2 tandem mass tag ratios with the median centering.</p>
    </sec>
    <sec id="sec1.3">
      <title>Implementation</title>
      <p id="p0065">The iProPhos web server is freely available to all users without login requirement for access. We built it on the R Shiny framework, using the HTML5, CSS, and Shiny JavaScript (shinyjs) libraries for rendering and interactive operations of front-end pages. The user interface layout is organized with a sidebar containing widgets for target inputs and options for analysis and visualization. The main panel displays the outputs in plot or table formats. Interactive tables were generated using the R package DT (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/DT/index.html" id="PC_linkjU1sp757lb">https://cran.r-project.org/web/packages/DT/index.html</ext-link>) to facilitate efficient data querying and selection. All outputs are available for download, with plots saved in PDF format as editable vector graphics compatible with vector graphic editors, such as Adobe Illustrator. iProPhos has been successfully tested on several browsers, including Google Chrome, Firefox, Internet Explorer (version 10 or later), and Safari. The R packages used in the web server are listed in <xref rid="appsec1" ref-type="sec">supplemental Table S2</xref>.</p>
    </sec>
  </sec>
  <sec id="sec2">
    <title>Results</title>
    <sec id="sec2.1">
      <title>iProPhos Performs Proteomics-Related Analyses</title>
      <p id="p0070">iProPhos can perform proteomics-related analyses and integrates transcriptomics data to investigate the complex relationships between gene expression and protein abundance in biological systems.</p>
      <p id="p0075">Differentially expressed proteins between tumor and normal samples drive tumorigenesis and progression. iProPhos conducts differential expression analysis using two approaches and presents the results with box plots and volcano plots (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>A</italic>). For the box plots, users can choose <italic>t</italic> test, Wilcoxon test, or ANOVA methods for hypothesis testing to evaluate the differences between two groups of samples. The <italic>t</italic> test is two-tailed and assumes unequal variances, and the Wilcoxon test is a Wilcoxon rank-sum test. The box color and point size are customizable. For the volcano plots, iProPhos fits a linear model to calculate the fold change and statistical significance of proteins using the R package limma (<xref rid="bib18" ref-type="bibr">18</xref>). Users can also set the cutoff value to define significance. Upregulated and downregulated proteins in tumor samples are labeled orange and blue respectively, whereas gray indicates nonsignificance. Moreover, a protein of interest can be magnified and highlighted with its gene symbol. The interactive table is displayed under a volcano plot containing the fold change and statistical significance data.<fig id="fig2"><label>Fig. 2</label><caption><p><bold>Proteome analysis module of iProPhos.</bold><italic>A</italic>, iProPhos presents differential expression analysis results with <italic>boxplots</italic> or <italic>volcano plots</italic>. <italic>B</italic>, the <italic>scatter plot</italic> illustrates the correlation between the abundance of two interested proteins, and the table displays the correlation of the abundance of one interested protein with the other detectable proteins in a given tumor type. <italic>C</italic>, Kaplan–Meier curves for overall survival. Patients are grouped based on the abundance of the protein of interest. <italic>D</italic>, iProPhos provides correlation analysis between mRNA and protein abundance. <italic>E</italic>–<italic>G</italic>, iProPhos provides clinical feature–related analysis for protein abundance, including age (<italic>E</italic>), gender (<italic>F</italic>), and tumor stage (<italic>G</italic>). <italic>H</italic>, iProPhos presents gene ontology (GO) enrichment analysis results with <italic>bar plots</italic> or <italic>dot plots</italic>. <italic>I</italic>, iProPhos presents Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analysis results with <italic>bar plots</italic> or <italic>dot plots</italic>. <italic>J</italic>, iProPhos can perform GSEA analysis for the target gene set. <italic>K</italic>, the PPI network map of proteins of interest. BP, biological process; CC, cell component; GSEA, gene set enrichment analysis; MF, molecular function; PPI, protein–protein interaction.</p></caption><graphic xlink:href="gr2"/></fig></p>
      <p id="p0080">Correlation analysis is essential for evaluating cooperative relationships between any two proteins. iProPhos delivers correlation results in the form of scatter plots or tables (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>B</italic>), allowing users to explore protein correlations conveniently. In the “Correlation Plot” tab panel, users can investigate correlations between two proteins of interest in a specific tumor and customize various graphic parameters (such as point size and color) and correlation measuring methods (<italic>e.g.</italic>, Pearson, Spearman, and Kendall correlations). In the “Correlation Table” tab panel, users can investigate correlations of the target protein with other proteins to gain biological ideas for further study.</p>
      <p id="p0085">Survival analysis can associate protein abundance with clinical outcomes and provide valuable insights for selecting potential drug targets. iProPhos provides two methods for calculating the cut-off value that divides patients into two groups. One method is to set the median value of protein abundance as the cutoff point, and the other is to utilize the surv_cutpoint algorithm applied in the R package survminer to determine the optimal cut-off point. The colors for these two groups are also customizable. iProPhos outputs Kaplan–Meier survival curves with log-rank <italic>p</italic> values and 95% confidence intervals (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>C</italic>).</p>
      <p id="p0090">Proteins are functionally relevant to phenotypes. However, the extent to which protein abundance correlates with the mRNA level and whether this correlation breaks down in some genes are not fully understood. mRNA-protein correlation analysis can refine our understanding of the principles of gene expression control in tumor cells (<xref rid="bib19" ref-type="bibr">19</xref>). iProPhos can perform correlation analysis between given mRNA and protein in the specific cancer type (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>D</italic>). The point size, color, and analysis methods are customizable.</p>
      <p id="p0095">iProPhos can investigate associations between protein abundance and clinical features, such as age, gender, and tumor stage (<xref rid="fig2" ref-type="fig">Fig. 2</xref>, <italic>E</italic>–<italic>G</italic>), which are crucial for identifying potential prognostic biomarkers and advancing personalized medicine. For age-relevant analysis, iProPhos allows users to choose the patients’ median age or to input a suitable number as the cutoff value. These analyses output the results with violin plots. The methods for differential analysis are optional, except for tumor stage-related analysis, where one-way ANOVA is required.</p>
      <p id="p0100">Enrichment analysis focuses on gene sets that share common biological attributes, helping researchers identify dysregulated pathways and generate hypothesises (<xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>). iProPhos performs over-representation analysis and gene set enrichment analysis (GSEA) using the R package clusterProfiler (<xref rid="bib22" ref-type="bibr">22</xref>). For over-representation analysis analysis, users can set a cut-off value to define differentially upregulated or downregulated proteins. Then functional enrichment analysis is performed based on Gene Ontology (<xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>) or Kyoto Encyclopedia of Genes and Genomes (<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>) annotations. Redundant Gene Ontology terms are removed using “simplify” method to present the most informative terms. The results are output in the table format and displayed with bar plots and dot plots (<xref rid="fig2" ref-type="fig">Fig. 2, H and I</xref>). For GSEA analysis, users can input the gene list of interest and rank genes based on the fold change from the differential expression analysis. The GSEA result is shown graphically, along with statistical significance (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>J</italic>).</p>
      <p id="p0105">PPI networks represent the relationships between proteins that are crucial for deciphering the mechanisms of cellular processes and diseases. iProPhos performs PPI network analysis using the R package stringdb (<xref rid="bib27" ref-type="bibr">27</xref>). Users can customize the cut-off value to define proteins for network analysis. iProPhos also generates an interactive network diagram of protein interactions (including both physical and functional interactions) (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>K</italic>). Nodes represent proteins, and edges represent their interactions, with thicker edges indicating a higher confidence of interactions. Additionally, users can download the results in tabular format for further analysis in Cytoscape (<ext-link ext-link-type="uri" xlink:href="https://cytoscape.org/" id="PC_linkGCNF8L3jHq">https://cytoscape.org/</ext-link>) or other similar software.</p>
    </sec>
    <sec id="sec2.2">
      <title>iProPhos Performs Phosphoproteomics-Related Analyses</title>
      <p id="p0110">iProPhos can perform phosphoproteomics-related analyses and integrate with proteomics data, gaining insights into the aberrant phosphorylation events associated with tumorigenesis and progression. The clinical feature-related analysis for phosphorylation level, including age, gender, and tumor stage (<xref rid="fig3" ref-type="fig">Fig. 3</xref>, <italic>A</italic>–<italic>C</italic>), and differential analysis comparing phosphorylation level of phosphosites between tumor and normal samples (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>D</italic>), are the same as those in the “Proteome Analysis” module. Therefore, these features are not repeated here.<fig id="fig3"><label>Fig. 3</label><caption><p><bold>Phosphoproteome analysis module of iProPhos.</bold><italic>A</italic>–<italic>C</italic>, iProPhos provides clinical feature–related analysis for phosphorylation level, including age (<italic>A</italic>), gender (<italic>B</italic>), and tumor stage (<italic>C</italic>). <italic>D</italic>, iProPhos presents differential phosphorylation level analysis results with <italic>boxplots</italic> or <italic>volcano plots</italic>. <italic>E</italic>, iProPhos provides correlation analysis between protein abundance and the phosphorylation level of the specific phosphosite. <italic>F</italic>, iProPhos conducts correlation analysis between protein abundance of kinases and phosphorylation levels of substrates. <italic>G</italic>, iProPhos estimates the changes in kinase activities in tumor samples compared to normal samples. The <italic>bar pl</italic>ot shows the normalized score for each kinase (z-score), weighted by the number of identified substrates. <italic>Red</italic> means significant activation in tumors, <italic>blue</italic> represents significant inactivation, and <italic>black</italic> denotes kinases with nonsignificant scores; the kinase scores table lists enrichment scores of all kinases; kinase-substrate links table shows the kinase and substrate relationships collected from the selected dataset. <italic>H</italic>, iProPhos performs overall survival analysis based on the phosphorylation level. The table shows the survival analysis results for all detected phosphosites of a given protein; Kaplan–Meier curves show the survival analysis result for a certain phosphosite. The statistical significance is determined by log-rank test.</p></caption><graphic xlink:href="gr3"/></fig></p>
      <p id="p0115">Studying the correlation between protein abundance and the phosphorylation levels of phosphosites provides new insights into the regulatory networks and mechanisms driving tumor progression. iProPhos can evaluate the correlation not only between proteins and their phosphosites but also between proteins and phosphosites on different proteins (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>E</italic>).</p>
      <p id="p0120">The abundance of some kinases correlates with their known substrate phosphorylation levels (<italic>e.g.</italic>, CDK1, CDK2) (<xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>). iProPhos can investigate correlations between the protein abundance of kinases and the phosphorylation levels of substrates. The results are presented with the table consisting of kinase-substrate links and the corresponding correlation coefficient and <italic>p</italic> value (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>F</italic>). These analyses can provide potential kinase-substrate pairs and reveal the complexity of signaling pathways and networks. The kinase list was collected from PhosphoSitePlus (<xref rid="bib30" ref-type="bibr">30</xref>) (<ext-link ext-link-type="uri" xlink:href="http://www.phosphosite.org" id="intref0025">http://www.phosphosite.org</ext-link>), a well-established resource containing expert-curated annotations, and NetworKIN (<xref rid="bib31" ref-type="bibr">31</xref>) (<ext-link ext-link-type="uri" xlink:href="https://networkin.info/" id="intref0030">https://networkin.info/</ext-link>), which consists of predicted kinase-substrate relationships obtained by integrating various data sources, including sequence-based predictions, experimental kinase-substrate relationships, and PPI networks.</p>
      <p id="p0125">iProPhos can estimate changes in kinase activity based on collective phosphorylation changes of identified substrates using the kinase-substrate enrichment analysis (KSEA) algorithm (<xref rid="bib32" ref-type="bibr">32</xref>). Differential phosphorylation analysis is performed between tumor and normal samples for a given tumor type using the R package limma, and the results are analyzed using the KSEA module. Users can choose the data sources of the kinase-substrate relationship. Among them, PhosphoSitePlus includes only experimentally verified kinase-substrate relationships, which is recommended for more conservative results. In contrast, NetworKIN provides the predicted relationships. iProPhos presents the results with graphic and tabular formats (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>G</italic>). The kinase scores are displayed with bar plots; kinases labeled red are predicted to be significantly activated in tumors, kinases labeled blue are predicted to be significantly inactivated, and black indicates nonsignificance. The list of kinase scores provides the enrichment scores of kinases with at least one identified substrate in the selected dataset, and the list of kinase-substrate links provides the kinase-substrate relationships collected from the selected dataset.</p>
      <p id="p0130">Exploring the correlation between phosphorylation levels and clinical outcomes is valuable for further studies. iProPhos generates a convenient table that provides survival analysis results for all detected phosphosites in a given protein (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>H</italic>). Using this function, users can easily select phosphosites that significantly correlate with survival outcomes. iProPhos provides the Kaplan–Meier survival curve plot using the log-rank test (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>H</italic>). The grouping methods and colors are customizable.</p>
    </sec>
    <sec id="sec2.3">
      <title>iProPhos can Identify Potential Drug Targets</title>
      <p id="p0135">Proteomics data provide an excellent opportunity to identify candidate proteins for future clinical treatments, potentially leading to beneficial outcomes. iProPhos has the ability to screen candidate targets. Take the instance of pancreatic ductal adenocarcinoma, which is a highly aggressive malignancy with the low survival rate (<xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>). First, we conducted differential expression analysis between tumor and normal samples using the limma algorithm based on protein abundance. To control the false discovery rate, we used Benjamini–Hochberg (BH) correction for all proteins and the same correction applies to all results in this article. Second, the Food and Drug Administration approved or candidate drug targets were extracted from the Human Protein Atlas. Overlapping proteins between drug targets and differentially expressed proteins (BH adjusted <italic>p</italic> &lt; 0.05) were selected for further analysis. Then, we focused on two proteins, PIEZO1 and PLAU, which were significantly upregulated in tumors (<xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>A</italic> and <italic>B</italic>). PIEZO1 is a mechanosensitive ion channel, which transduces various mechanical stimulations into electrochemical signals (<xref rid="bib35" ref-type="bibr">35</xref>), and PLAU is a serine protease, which promotes fibrinolysis and degradation of extracellular matrix (<xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>). In addition, we also employed the Wilcoxon test to validate the differences in protein abundance (PIEZO1, BH adjusted <italic>p</italic> = 1.3e-04; PLAU, BH adjusted <italic>p</italic> = 1.6e-22; <xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>C</italic> and <italic>D</italic>). Furthermore, we performed survival analysis to investigate the possibility of these two proteins as drug targets. Based on the optimal cut-off point, we classified patients into high- and low-expression groups and found a significant survival difference between them. The high-expression group exhibited a poorer survival outcome than the low-expression group (log-rank test, BH adjusted <italic>p</italic> = 0.027, and BH adjusted <italic>p</italic> = 0.014 for PIEZO1 and PLAU, respectively; <xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>E</italic> and <italic>F</italic>). Moreover, we found that PLAU genes exhibited significantly positive correlation between mRNA expression and its protein abundance, while PIEZO1 showed a weaker correlation (R = 0.75, BH adjusted <italic>p</italic> = 4.5e-24 for PLAU; R = 0.24, BH adjusted <italic>p</italic> = 7.7e-03 for PIEZO1; <xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>G</italic> and <italic>H</italic>). These findings highlight the importance of direct exploration of protein expression profiles, as relying solely on mRNA expression may overlook the critical information regarding protein regulation and function.<fig id="fig4"><label>Fig. 4</label><caption><p><bold>iProPhos could reveal potential drug targets and infer crucial phosphosites and their upstream kinases.</bold><italic>A</italic> and <italic>B</italic>, <italic>volcano plots</italic> show that PIEZO1 (<italic>A</italic>) and PLAU (<italic>B</italic>) are significantly upregulated in PDA (Benjamini–Hochberg [BH] adjusted <italic>p</italic> &lt; 0.05). <italic>C</italic> and <italic>D</italic>, PIEZO1 (<italic>C</italic>) and PLAU (<italic>D</italic>) show significantly higher expression in PDA. <italic>E</italic> and <italic>F</italic>, survival analysis of PDA patients based on the protein abundance of PIEZO1 (<italic>E</italic>) and PLAU (<italic>F</italic>). <italic>G</italic> and <italic>H</italic>, Pearson’s correlation analysis between mRNA and protein abundance of PIEZO1 (<italic>G</italic>) and PLAU (<italic>H</italic>). <italic>I</italic>, evaluation of kinase activity changes by kinase-substrate enrichment analysis in HCC. <italic>Red</italic> means significant activation in tumors, <italic>blue</italic> represents significant inactivation, and <italic>black</italic> denotes kinases with nonsignificant scores. <italic>J</italic>, Pearson’s correlation analysis between CDK1 abundance and the phosphorylation level of NCL-S67. <italic>K</italic>, <italic>boxplot</italic> shows that phosphorylation level of NCL-S67 is significantly upregulated in HCC. <italic>L</italic>, survival analysis of HCC patients based on the phosphorylation level of NCL-S67. HCC, hepatocellular carcinoma; PDA, pancreatic ductal adenocarcinoma.</p></caption><graphic xlink:href="gr4"/></fig></p>
      <p id="p0140">In summary, iProPhos is a valuable tool that enables researchers to conveniently explore cancer proteomics and identify potential drug targets.</p>
    </sec>
    <sec id="sec2.4">
      <title>iProPhos can Identify Crucial Phosphosites and Their Upstream Kinases</title>
      <p id="p0145">The identification of kinase-substrate relationships is crucial for understanding phosphorylation signals. Take the example of hepatocellular carcinoma (HCC), iProPhos inferred kinase activity changes using the KSEA method. Kinase-substrate annotations were obtained from PhosphoSitePlus and NetworKIN, and the NetworkKIN score cut-off was set to 8. Results showed a significant upregulation of the activity of CSNK2A1, CDK1, PLK1, PRKDC, and CDK2 in HCC (<xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>I</italic> and <xref rid="appsec1" ref-type="sec">supplemental Table S3</xref>). CDK1 plays a critical role in cell cycle progression, and the overactivation of CDK1 has been identified to be closely associated with tumorigenesis (<xref rid="bib38" ref-type="bibr">38</xref>). NCL-S67 was inferred to be the substrate of CDK1 (<xref rid="appsec1" ref-type="sec">supplemental Table S4</xref>). We further investigated the correlation between the protein abundance of CDK1 and the phosphorylation level of NCL-S67. The results demonstrated a significantly positive correlation between them (R = 0.81, BH adjusted <italic>p</italic> = 3.3e-25; <xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>J</italic>). We also found that the phosphorylation level of NCL-S67 was significantly upregulated in HCC compared with matched normal samples (Wilcoxon test, BH adjusted <italic>p</italic> = 2.1e-37; <xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>K</italic>). Next, we performed survival analysis using the median phosphorylation level of NCL-S67 as the cut-off value, finding that the high-expression group had a worse prognosis (log-rank test, BH adjusted <italic>p</italic> = 1.8e-03; <xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>L</italic>). These results demonstrate that iProPhos is a powerful tool for discovering critical phosphorylation events, which can ultimately improve our understanding of disease biology.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Discussion</title>
    <p id="p0150">Mass spectrometry–based proteomics is a widely effective method for identifying, characterizing, and quantifying proteins. Proteins play an indispensable role in biological processes, and PTMs of proteins can regulate the biological functions of cells. The presence of PTMs increases the chemical diversity and complexity of the proteins, making comprehensive analysis of proteomics crucial for understanding cancer biology. However, genomics and transcriptomics methods fail to capture information about PTMs, making proteomics the sole approach for large-scale study of these modifications.</p>
    <p id="p0155">In high-throughput proteomics, analyzing and interpreting quantitative results to propose biological or clinical hypotheses is an ongoing challenge. Currently, there is a scarcity of comprehensive analysis and visualization tools for proteomics data, particularly in phosphoproteomics. Therefore, we have developed iProPhos, a user-friendly web server that provides a comprehensive and integrated analysis platform for proteome and phosphoproteome data. iProPhos can not only separately explore proteomics/phosphoproteomics differences between sample groups, but also integrate proteomics with transcriptomics or phosphoproteomics. iProPhos has the competency of hosting more abundant analyses such as differential expression, patient survival, clinical feature-related, kinase-substrate enrichment, and correlation analyses, including protein–protein, mRNA-protein, and kinase-substrate correlations. In addition, iProPhos provides downstream functional enrichment analysis and PPI network analysis, enabling researchers to gain deeper insights into the functional implications and interactions of the proteins of interest. The extensive analyses provided by iProPhos, accessible with only a few clicks, enable researchers without programming skills to perform multiple analyses. Moreover, iProPhos provides a series of optional parameters for plotting and statistical analysis, helping generate publication-ready figures.</p>
    <p id="p0160">Most existing analysis tools focus on the transcriptome, but protein and mRNA levels exhibit discrepancies in certain genes (<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>). A previous study explored mRNA-protein correlations across 32 normal human tissues for each gene, finding that the median Spearman correlation was 0.46 (<xref rid="bib41" ref-type="bibr">41</xref>). It is suggested that proteomics data provide additional information missing in transcriptomic studies, facilitating a more comprehensive understanding of tumor development and the discovery of novel therapeutic strategies. Moreover, phosphoproteomics studies and their integrated analysis with proteomics data further enrich the breadth of the study, enabling the exploration of critical phosphorylation events and kinase-substrate relationships, which fill the gaps in a single-layer analysis and enhance our understanding of the molecular mechanisms underlying the disease.</p>
    <p id="p0165">Due to the limitation of available datasets integrating transcriptome, proteome, and phosphoproteome, iProPhos has collected omics data from only 12 cancer types. In the future, we will continue to incorporate more tumor proteomics datasets, including different cancer types. Moreover, we consider integrating proteomics data from various cancer cell lines in the next version, as these models provide valuable insights into understanding cellular processes and the underlying factors driving carcinogenesis. iProPhos currently provides correlation analysis for paired proteins, but it cannot identify biological networks based on pairwise correlations. In future iterations, iProPhos will provide weighted gene coexpression network analysis to find highly correlated protein clusters and identify hub proteins within those clusters. Furthermore, iProPhos will utilize advanced machine learning algorithms to enhance the efficiency and accuracy of biomarker identification. iProPho will be updated continuously and provide researchers with a powerful tool for studying the role of proteins and PTMs in tumor progression and further leveraging the value of big data in cancer proteomics.</p>
    <p id="p0170">In summary, iProPhos is an intuitive and time-saving tool for the cancer community to dissect oncogenic signaling networks and address unmet clinical needs. Its comprehensive analysis capabilities, integration of different omics data, and potential for biomarker identification make it a valuable asset to unravel the complexities of cancer biology and develop novel therapeutic interventions.</p>
  </sec>
  <sec sec-type="data-availability" id="sec4">
    <title>Data Availability</title>
    <p id="p0175">iProPhos is free and open to all users, with no login requirement. Transcriptome, proteome, phosphoproteome, and clinical data across 12 cancer types were sourced from the CPTAC data portal (<ext-link ext-link-type="uri" xlink:href="https://proteomic.datacommons.cancer.gov/pdc/" id="intref0035">https://proteomic.datacommons.cancer.gov/pdc/</ext-link>). The code for producing iProPhos will be deposited to GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/longLabzj/iProPhos/" id="intref0040">https://github.com/longLabzj/iProPhos/</ext-link>), and will be publicly available upon publication.</p>
  </sec>
  <sec sec-type="supplementary-material" id="sec5">
    <title>Supplemental Data</title>
    <p id="p0180">This article contains <xref rid="appsec1" ref-type="sec">supplemental data</xref>.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p id="p0185">The authors declare no competing interests.</p>
  </sec>
</body>
<back>
  <ref-list id="cebib0010">
    <title>References</title>
    <ref id="bib1">
      <label>1</label>
      <element-citation publication-type="journal" id="sref1">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>Yaffe</surname>
            <given-names>M.B.</given-names>
          </name>
        </person-group>
        <article-title>Protein regulation in signal transduction</article-title>
        <source>Cold Spring Harb. Perspect. Biol.</source>
        <volume>8</volume>
        <year>2016</year>
        <object-id pub-id-type="publisher-id">a005918</object-id>
      </element-citation>
    </ref>
    <ref id="bib2">
      <label>2</label>
      <element-citation publication-type="journal" id="sref2">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Tong</surname>
            <given-names>R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials</article-title>
        <source>Signal. Transduct. Target. Ther.</source>
        <volume>5</volume>
        <year>2020</year>
        <fpage>213</fpage>
        <pub-id pub-id-type="pmid">32968059</pub-id>
      </element-citation>
    </ref>
    <ref id="bib3">
      <label>3</label>
      <element-citation publication-type="journal" id="sref3">
        <person-group person-group-type="author">
          <name>
            <surname>Timp</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Timp</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>Beyond mass spectrometry, the next step in proteomics</article-title>
        <source>Sci. Adv.</source>
        <volume>6</volume>
        <year>2020</year>
        <object-id pub-id-type="publisher-id">eaax8978</object-id>
      </element-citation>
    </ref>
    <ref id="bib4">
      <label>4</label>
      <element-citation publication-type="journal" id="sref4">
        <person-group person-group-type="author">
          <name>
            <surname>Bilbrough</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Piemontese</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Seitz</surname>
            <given-names>O.</given-names>
          </name>
        </person-group>
        <article-title>Dissecting the role of protein phosphorylation: a chemical biology toolbox</article-title>
        <source>Chem. Soc. Rev.</source>
        <volume>51</volume>
        <year>2022</year>
        <fpage>5691</fpage>
        <lpage>5730</lpage>
        <pub-id pub-id-type="pmid">35726784</pub-id>
      </element-citation>
    </ref>
    <ref id="bib5">
      <label>5</label>
      <element-citation publication-type="journal" id="sref5">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>Z.H.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z.Y.</given-names>
          </name>
        </person-group>
        <article-title>Regulatory mechanisms and novel therapeutic targeting strategies for protein tyrosine phosphatases</article-title>
        <source>Chem. Rev.</source>
        <volume>118</volume>
        <year>2018</year>
        <fpage>1069</fpage>
        <lpage>1091</lpage>
        <pub-id pub-id-type="pmid">28541680</pub-id>
      </element-citation>
    </ref>
    <ref id="bib6">
      <label>6</label>
      <element-citation publication-type="journal" id="sref6">
        <person-group person-group-type="author">
          <name>
            <surname>Hunter</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling</article-title>
        <source>Cell</source>
        <volume>80</volume>
        <year>1995</year>
        <fpage>225</fpage>
        <lpage>236</lpage>
        <pub-id pub-id-type="pmid">7834742</pub-id>
      </element-citation>
    </ref>
    <ref id="bib7">
      <label>7</label>
      <element-citation publication-type="journal" id="sref7">
        <person-group person-group-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>E.C.B.</given-names>
          </name>
          <name>
            <surname>Carter</surname>
            <given-names>E.K.</given-names>
          </name>
          <name>
            <surname>Dammer</surname>
            <given-names>E.B.</given-names>
          </name>
          <name>
            <surname>Duong</surname>
            <given-names>D.M.</given-names>
          </name>
          <name>
            <surname>Gerasimov</surname>
            <given-names>E.S.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level</article-title>
        <source>Nat. Neurosci.</source>
        <volume>25</volume>
        <year>2022</year>
        <fpage>213</fpage>
        <lpage>225</lpage>
        <pub-id pub-id-type="pmid">35115731</pub-id>
      </element-citation>
    </ref>
    <ref id="bib8">
      <label>8</label>
      <element-citation publication-type="journal" id="sref8">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Beyer</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Aebersold</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>On the dependency of cellular protein levels on mRNA abundance</article-title>
        <source>Cell</source>
        <volume>165</volume>
        <year>2016</year>
        <fpage>535</fpage>
        <lpage>550</lpage>
        <pub-id pub-id-type="pmid">27104977</pub-id>
      </element-citation>
    </ref>
    <ref id="bib9">
      <label>9</label>
      <element-citation publication-type="journal" id="sref9">
        <person-group person-group-type="author">
          <name>
            <surname>Giudice</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Petsalaki</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>Proteomics and phosphoproteomics in precision medicine: applications and challenges</article-title>
        <source>Brief. Bioinform.</source>
        <volume>20</volume>
        <year>2019</year>
        <fpage>767</fpage>
        <lpage>777</lpage>
        <pub-id pub-id-type="pmid">29077858</pub-id>
      </element-citation>
    </ref>
    <ref id="bib10">
      <label>10</label>
      <element-citation publication-type="journal" id="sref10">
        <person-group person-group-type="author">
          <name>
            <surname>Aebersold</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Mann</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Mass spectrometry-based proteomics</article-title>
        <source>Nature</source>
        <volume>422</volume>
        <year>2003</year>
        <fpage>198</fpage>
        <lpage>207</lpage>
        <pub-id pub-id-type="pmid">12634793</pub-id>
      </element-citation>
    </ref>
    <ref id="bib11">
      <label>11</label>
      <element-citation publication-type="journal" id="sref11">
        <person-group person-group-type="author">
          <name>
            <surname>Meissner</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Geddes-McAlister</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mann</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bantscheff</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>The emerging role of mass spectrometry-based proteomics in drug discovery</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <volume>21</volume>
        <year>2022</year>
        <fpage>637</fpage>
        <lpage>654</lpage>
        <pub-id pub-id-type="pmid">35351998</pub-id>
      </element-citation>
    </ref>
    <ref id="bib12">
      <label>12</label>
      <element-citation publication-type="journal" id="sref12">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Akbani</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Ju</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Roebuck</surname>
            <given-names>P.L.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TCPA: a resource for cancer functional proteomics data</article-title>
        <source>Nat. Methods</source>
        <volume>10</volume>
        <year>2013</year>
        <fpage>1046</fpage>
        <lpage>1047</lpage>
      </element-citation>
    </ref>
    <ref id="bib13">
      <label>13</label>
      <element-citation publication-type="journal" id="sref13">
        <person-group person-group-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>G.S.</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>Z.Z.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>Y.H.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>D.C.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>CPPA: a web tool for exploring proteomic and phosphoproteomic data in cancer</article-title>
        <source>J. Proteome Res.</source>
        <volume>22</volume>
        <year>2023</year>
        <fpage>368</fpage>
        <lpage>373</lpage>
        <pub-id pub-id-type="pmid">36507870</pub-id>
      </element-citation>
    </ref>
    <ref id="bib14">
      <label>14</label>
      <element-citation publication-type="journal" id="sref14">
        <person-group person-group-type="author">
          <name>
            <surname>Chandrashekar</surname>
            <given-names>D.S.</given-names>
          </name>
          <name>
            <surname>Karthikeyan</surname>
            <given-names>S.K.</given-names>
          </name>
          <name>
            <surname>Korla</surname>
            <given-names>P.K.</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Shovon</surname>
            <given-names>A.R.</given-names>
          </name>
          <name>
            <surname>Athar</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>UALCAN: an update to the integrated cancer data analysis platform</article-title>
        <source>Neoplasia</source>
        <volume>25</volume>
        <year>2022</year>
        <fpage>18</fpage>
        <lpage>27</lpage>
        <pub-id pub-id-type="pmid">35078134</pub-id>
      </element-citation>
    </ref>
    <ref id="bib15">
      <label>15</label>
      <element-citation publication-type="journal" id="sref15">
        <person-group person-group-type="author">
          <name>
            <surname>Vasaikar</surname>
            <given-names>S.V.</given-names>
          </name>
          <name>
            <surname>Straub</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B.</given-names>
          </name>
        </person-group>
        <article-title>LinkedOmics: analyzing multi-omics data within and across 32 cancer types</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>46</volume>
        <year>2018</year>
        <fpage>D956</fpage>
        <lpage>D963</lpage>
        <pub-id pub-id-type="pmid">29136207</pub-id>
      </element-citation>
    </ref>
    <ref id="bib16">
      <label>16</label>
      <element-citation publication-type="journal" id="sref16">
        <person-group person-group-type="author">
          <name>
            <surname>Edwards</surname>
            <given-names>N.J.</given-names>
          </name>
          <name>
            <surname>Oberti</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Thangudu</surname>
            <given-names>R.R.</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>McGarvey</surname>
            <given-names>P.B.</given-names>
          </name>
          <name>
            <surname>Jacob</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The CPTAC data portal: a resource for cancer proteomics research</article-title>
        <source>J. Proteome Res.</source>
        <volume>14</volume>
        <year>2015</year>
        <fpage>2707</fpage>
        <lpage>2713</lpage>
        <pub-id pub-id-type="pmid">25873244</pub-id>
      </element-citation>
    </ref>
    <ref id="bib17">
      <label>17</label>
      <element-citation publication-type="journal" id="sref17">
        <person-group person-group-type="author">
          <name>
            <surname>Rudnick</surname>
            <given-names>P.A.</given-names>
          </name>
          <name>
            <surname>Markey</surname>
            <given-names>S.P.</given-names>
          </name>
          <name>
            <surname>Roth</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mirokhin</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Tchekhovskoi</surname>
            <given-names>D.V.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A description of the clinical proteomic tumor analysis consortium (CPTAC) common data analysis pipeline</article-title>
        <source>J. Proteome Res.</source>
        <volume>15</volume>
        <year>2016</year>
        <fpage>1023</fpage>
        <lpage>1032</lpage>
        <pub-id pub-id-type="pmid">26860878</pub-id>
      </element-citation>
    </ref>
    <ref id="bib18">
      <label>18</label>
      <element-citation publication-type="journal" id="sref18">
        <person-group person-group-type="author">
          <name>
            <surname>Ritchie</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Phipson</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Law</surname>
            <given-names>C.W.</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>43</volume>
        <year>2015</year>
        <fpage>e47</fpage>
        <pub-id pub-id-type="pmid">25605792</pub-id>
      </element-citation>
    </ref>
    <ref id="bib19">
      <label>19</label>
      <element-citation publication-type="journal" id="sref19">
        <person-group person-group-type="author">
          <name>
            <surname>Buccitelli</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Selbach</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>mRNAs, proteins and the emerging principles of gene expression control</article-title>
        <source>Nat. Rev. Genet.</source>
        <volume>21</volume>
        <year>2020</year>
        <fpage>630</fpage>
        <lpage>644</lpage>
        <pub-id pub-id-type="pmid">32709985</pub-id>
      </element-citation>
    </ref>
    <ref id="bib20">
      <label>20</label>
      <element-citation publication-type="journal" id="sref20">
        <person-group person-group-type="author">
          <name>
            <surname>Subramanian</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Tamayo</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Mootha</surname>
            <given-names>V.K.</given-names>
          </name>
          <name>
            <surname>Mukherjee</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ebert</surname>
            <given-names>B.L.</given-names>
          </name>
          <name>
            <surname>Gillette</surname>
            <given-names>M.A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>
        <source>Proc. Natl. Acad. Sci. U. S. A.</source>
        <volume>102</volume>
        <year>2005</year>
        <fpage>15545</fpage>
        <lpage>15550</lpage>
        <pub-id pub-id-type="pmid">16199517</pub-id>
      </element-citation>
    </ref>
    <ref id="bib21">
      <label>21</label>
      <element-citation publication-type="journal" id="sref21">
        <person-group person-group-type="author">
          <name>
            <surname>Tipney</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Hunter</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>An introduction to effective use of enrichment analysis software</article-title>
        <source>Hum. Genomics</source>
        <volume>4</volume>
        <year>2010</year>
        <fpage>202</fpage>
        <lpage>206</lpage>
        <pub-id pub-id-type="pmid">20368141</pub-id>
      </element-citation>
    </ref>
    <ref id="bib22">
      <label>22</label>
      <element-citation publication-type="journal" id="sref22">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>clusterProfiler 4.0: a universal enrichment tool for interpreting omics data</article-title>
        <source>Innovation (Camb.)</source>
        <volume>2</volume>
        <year>2021</year>
        <object-id pub-id-type="publisher-id">100141</object-id>
      </element-citation>
    </ref>
    <ref id="bib23">
      <label>23</label>
      <element-citation publication-type="journal" id="sref23">
        <person-group person-group-type="author">
          <name>
            <surname>Ashburner</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ball</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Blake</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Botstein</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Butler</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Cherry</surname>
            <given-names>J.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene ontology: tool for the unification of biology. The Gene Ontology Consortium</article-title>
        <source>Nat. Genet.</source>
        <volume>25</volume>
        <year>2000</year>
        <fpage>25</fpage>
        <lpage>29</lpage>
        <pub-id pub-id-type="pmid">10802651</pub-id>
      </element-citation>
    </ref>
    <ref id="bib24">
      <label>24</label>
      <element-citation publication-type="journal" id="sref24">
        <person-group person-group-type="author">
          <name>
            <surname>Gene Ontology</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>The gene ontology resource: enriching a GOld mine</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>49</volume>
        <year>2021</year>
        <fpage>D325</fpage>
        <lpage>D334</lpage>
        <pub-id pub-id-type="pmid">33290552</pub-id>
      </element-citation>
    </ref>
    <ref id="bib25">
      <label>25</label>
      <element-citation publication-type="journal" id="sref25">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Goto</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>28</volume>
        <year>2000</year>
        <fpage>27</fpage>
        <lpage>30</lpage>
        <pub-id pub-id-type="pmid">10592173</pub-id>
      </element-citation>
    </ref>
    <ref id="bib26">
      <label>26</label>
      <element-citation publication-type="journal" id="sref26">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Furumichi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Tanabe</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Morishima</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>45</volume>
        <year>2017</year>
        <fpage>D353</fpage>
        <lpage>D361</lpage>
        <pub-id pub-id-type="pmid">27899662</pub-id>
      </element-citation>
    </ref>
    <ref id="bib27">
      <label>27</label>
      <element-citation publication-type="journal" id="sref27">
        <person-group person-group-type="author">
          <name>
            <surname>Szklarczyk</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Gable</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Nastou</surname>
            <given-names>K.C.</given-names>
          </name>
          <name>
            <surname>Lyon</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Kirsch</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Pyysalo</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>49</volume>
        <year>2021</year>
        <fpage>D605</fpage>
        <lpage>D612</lpage>
        <pub-id pub-id-type="pmid">33237311</pub-id>
      </element-citation>
    </ref>
    <ref id="bib28">
      <label>28</label>
      <element-citation publication-type="journal" id="sref28">
        <person-group person-group-type="author">
          <name>
            <surname>Petralia</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Tignor</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Reva</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Koptyra</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Chowdhury</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Rykunov</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated proteogenomic characterization across major histological types of pediatric brain cancer</article-title>
        <source>Cell</source>
        <volume>183</volume>
        <year>2020</year>
        <fpage>1962</fpage>
        <lpage>1985.e31</lpage>
        <pub-id pub-id-type="pmid">33242424</pub-id>
      </element-citation>
    </ref>
    <ref id="bib29">
      <label>29</label>
      <element-citation publication-type="journal" id="sref29">
        <person-group person-group-type="author">
          <name>
            <surname>Arshad</surname>
            <given-names>O.A.</given-names>
          </name>
          <name>
            <surname>Danna</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Petyuk</surname>
            <given-names>V.A.</given-names>
          </name>
          <name>
            <surname>Piehowski</surname>
            <given-names>P.D.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Rodland</surname>
            <given-names>K.D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>An integrative analysis of tumor proteomic and phosphoproteomic profiles to examine the relationships between kinase activity and phosphorylation</article-title>
        <source>Mol. Cell. Proteomics</source>
        <volume>18</volume>
        <year>2019</year>
        <fpage>S26</fpage>
        <lpage>S36</lpage>
        <pub-id pub-id-type="pmid">31227600</pub-id>
      </element-citation>
    </ref>
    <ref id="bib30">
      <label>30</label>
      <element-citation publication-type="journal" id="sref30">
        <person-group person-group-type="author">
          <name>
            <surname>Hornbeck</surname>
            <given-names>P.V.</given-names>
          </name>
          <name>
            <surname>Kornhauser</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Tkachev</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Skrzypek</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>40</volume>
        <year>2012</year>
        <fpage>D261</fpage>
        <lpage>D270</lpage>
        <pub-id pub-id-type="pmid">22135298</pub-id>
      </element-citation>
    </ref>
    <ref id="bib31">
      <label>31</label>
      <element-citation publication-type="journal" id="sref31">
        <person-group person-group-type="author">
          <name>
            <surname>Linding</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>L.J.</given-names>
          </name>
          <name>
            <surname>Ostheimer</surname>
            <given-names>G.J.</given-names>
          </name>
          <name>
            <surname>van Vugt</surname>
            <given-names>M.A.T.M.</given-names>
          </name>
          <name>
            <surname>Jørgensen</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Miron</surname>
            <given-names>I.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Systematic discovery of in vivo phosphorylation networks</article-title>
        <source>Cell</source>
        <volume>129</volume>
        <year>2007</year>
        <fpage>1415</fpage>
        <lpage>1426</lpage>
        <pub-id pub-id-type="pmid">17570479</pub-id>
      </element-citation>
    </ref>
    <ref id="bib32">
      <label>32</label>
      <element-citation publication-type="journal" id="sref32">
        <person-group person-group-type="author">
          <name>
            <surname>Wiredja</surname>
            <given-names>D.D.</given-names>
          </name>
          <name>
            <surname>Koyuturk</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Chance</surname>
            <given-names>M.R.</given-names>
          </name>
        </person-group>
        <article-title>The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics</article-title>
        <source>Bioinformatics</source>
        <volume>33</volume>
        <year>2017</year>
        <fpage>3489</fpage>
        <lpage>3491</lpage>
        <pub-id pub-id-type="pmid">28655153</pub-id>
      </element-citation>
    </ref>
    <ref id="bib33">
      <label>33</label>
      <element-citation publication-type="journal" id="sref33">
        <person-group person-group-type="author">
          <name>
            <surname>Hutcheson</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Balaji</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Porembka</surname>
            <given-names>M.R.</given-names>
          </name>
          <name>
            <surname>Wachsmann</surname>
            <given-names>M.B.</given-names>
          </name>
          <name>
            <surname>McCue</surname>
            <given-names>P.A.</given-names>
          </name>
          <name>
            <surname>Knudsen</surname>
            <given-names>E.S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Immunologic and metabolic features of pancreatic ductal adenocarcinoma define prognostic subtypes of disease</article-title>
        <source>Clin. Cancer Res.</source>
        <volume>22</volume>
        <year>2016</year>
        <fpage>3606</fpage>
        <lpage>3617</lpage>
        <pub-id pub-id-type="pmid">26858311</pub-id>
      </element-citation>
    </ref>
    <ref id="bib34">
      <label>34</label>
      <element-citation publication-type="journal" id="sref34">
        <person-group person-group-type="author">
          <name>
            <surname>Payen</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Oberstein</surname>
            <given-names>P.E.</given-names>
          </name>
          <name>
            <surname>Saharkhiz</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Palermo</surname>
            <given-names>C.F.</given-names>
          </name>
          <name>
            <surname>Sastra</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Harmonic motion imaging of pancreatic tumor stiffness indicates disease state and treatment response</article-title>
        <source>Clin. Cancer Res.</source>
        <volume>26</volume>
        <year>2020</year>
        <fpage>1297</fpage>
        <lpage>1308</lpage>
        <pub-id pub-id-type="pmid">31831559</pub-id>
      </element-citation>
    </ref>
    <ref id="bib35">
      <label>35</label>
      <element-citation publication-type="journal" id="sref35">
        <person-group person-group-type="author">
          <name>
            <surname>Lai</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Cox</surname>
            <given-names>C.D.</given-names>
          </name>
          <name>
            <surname>Chandra Sekar</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Thurgood</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Jaworowski</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Peter</surname>
            <given-names>K.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mechanosensing by Piezo1 and its implications for physiology and various pathologies</article-title>
        <source>Biol. Rev. Camb. Philos. Soc.</source>
        <volume>97</volume>
        <year>2022</year>
        <fpage>604</fpage>
        <lpage>614</lpage>
        <pub-id pub-id-type="pmid">34781417</pub-id>
      </element-citation>
    </ref>
    <ref id="bib36">
      <label>36</label>
      <element-citation publication-type="journal" id="sref36">
        <person-group person-group-type="author">
          <name>
            <surname>Fang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Che</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lei</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF-kappaB/IL8 pathway</article-title>
        <source>Cell Death Discov.</source>
        <volume>7</volume>
        <year>2021</year>
        <fpage>32</fpage>
        <pub-id pub-id-type="pmid">33574243</pub-id>
      </element-citation>
    </ref>
    <ref id="bib37">
      <label>37</label>
      <element-citation publication-type="journal" id="sref37">
        <person-group person-group-type="author">
          <name>
            <surname>Sudol</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management</article-title>
        <source>Oncogene</source>
        <volume>30</volume>
        <year>2011</year>
        <fpage>3003</fpage>
        <lpage>3010</lpage>
        <pub-id pub-id-type="pmid">21383693</pub-id>
      </element-citation>
    </ref>
    <ref id="bib38">
      <label>38</label>
      <element-citation publication-type="journal" id="sref38">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Q.S.</given-names>
          </name>
          <name>
            <surname>Bode</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>T.S.</given-names>
          </name>
        </person-group>
        <article-title>Targeting CDK1 in cancer: mechanisms and implications</article-title>
        <source>NPJ Precis. Oncol.</source>
        <volume>7</volume>
        <year>2023</year>
        <fpage>58</fpage>
        <pub-id pub-id-type="pmid">37311884</pub-id>
      </element-citation>
    </ref>
    <ref id="bib39">
      <label>39</label>
      <element-citation publication-type="journal" id="sref39">
        <person-group person-group-type="author">
          <name>
            <surname>Fortelny</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Overall</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Pavlidis</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Freue</surname>
            <given-names>G.V.C.</given-names>
          </name>
        </person-group>
        <article-title>Can we predict protein from mRNA levels?</article-title>
        <source>Nature</source>
        <volume>547</volume>
        <year>2017</year>
        <fpage>E19</fpage>
        <lpage>E20</lpage>
        <pub-id pub-id-type="pmid">28748932</pub-id>
      </element-citation>
    </ref>
    <ref id="bib40">
      <label>40</label>
      <element-citation publication-type="journal" id="sref40">
        <person-group person-group-type="author">
          <name>
            <surname>Franks</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Airoldi</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Slavov</surname>
            <given-names>N.</given-names>
          </name>
        </person-group>
        <article-title>Post-transcriptional regulation across human tissues</article-title>
        <source>PLoS Comput. Biol.</source>
        <volume>13</volume>
        <year>2017</year>
        <object-id pub-id-type="publisher-id">e1005535</object-id>
      </element-citation>
    </ref>
    <ref id="bib41">
      <label>41</label>
      <element-citation publication-type="journal" id="sref41">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Jian</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A quantitative proteome map of the human body</article-title>
        <source>Cell</source>
        <volume>183</volume>
        <year>2020</year>
        <fpage>269</fpage>
        <lpage>283.e19</lpage>
        <pub-id pub-id-type="pmid">32916130</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="appsec1" sec-type="supplementary-material">
    <title>Supplemental Data</title>
    <p id="p0200">
      <supplementary-material content-type="local-data" id="mmc1">
        <caption>
          <title>Supplemental Tables S1–S4</title>
        </caption>
        <media xlink:href="mmc1.xlsx"/>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ack0010">
    <title>Acknowledgments</title>
    <p id="p0205">This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100012166</institution-id><institution>National Key R&amp;D Program of China</institution></institution-wrap></funding-source> (2021YFA1101000 and 2022YFA1105200), the <funding-source id="gs2">Chinese National Natural Science Funds</funding-source> (U20A20393, 32270975, 32070907, 92169122, 82371841, 32100699, 31771619, 32200575, and 22074132), the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100014219</institution-id><institution>National Science Fund for Distinguished Young Scholars</institution></institution-wrap></funding-source> (32125016 and 31925013), the <funding-source id="gs4">China National Postdoctoral Program for Innovative Talents</funding-source> (BX2021208), the <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source> (2021M692350) and <funding-source id="gs6">Suzhou Innovation and Entrepreneurship Leading Talent Program</funding-source> (ZXL2022505, ZXL2022442, and ZXL2023206), Key Cross-Research Projects of the School of Medicine, <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100022956</institution-id><institution>Soochow University</institution></institution-wrap></funding-source> (YXY2303027), and the <funding-source id="gs8">Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases</funding-source>. Additionally, we acknowledge the support from the <funding-source id="gs9">Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases</funding-source>，the platform of the <funding-source id="gs10">Zhejiang University School of Medicine</funding-source> and the <funding-source id="gs11">Life Sciences Institute</funding-source>.</p>
    <sec id="sec6">
      <title>Author contributions</title>
      <p id="p0195">J. Z., Z. Q., and R. L., methodology; J. Z. and Z. Q. writing-original draft; J. Z. software; Z. Q. visualization; X. Y., H. H., B. Y., F. Z., and L. Z. conceptualization; X. Y., H. H., F. Z., and L. Z. writing–review and editing.</p>
    </sec>
  </ack>
</back>
<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_MCPRO100693 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEgr4 jpg ?>
<?FILEga1 jpg ?>
<?FILEmmc1 xlsx ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Mol Cell Proteomics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Mol Cell Proteomics</journal-id>
    <journal-title-group>
      <journal-title>Molecular &amp; Cellular Proteomics : MCP</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1535-9476</issn>
    <issn pub-type="epub">1535-9484</issn>
    <publisher>
      <publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10828474</article-id>
    <article-id pub-id-type="pii">S1535-9476(23)00204-9</article-id>
    <article-id pub-id-type="doi">10.1016/j.mcpro.2023.100693</article-id>
    <article-id pub-id-type="publisher-id">100693</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Technological Innovation and Resources</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>iProPhos: A Web-Based Interactive Platform for Integrated Proteome and Phosphoproteome Analysis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au1">
        <name>
          <surname>Zou</surname>
          <given-names>Jing</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="au2">
        <name>
          <surname>Qin</surname>
          <given-names>Ziran</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="au3">
        <name>
          <surname>Li</surname>
          <given-names>Ran</given-names>
        </name>
        <email>ranli1993@zju.edu.cn</email>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="fn1" ref-type="fn">‡</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <contrib contrib-type="author" id="au4">
        <name>
          <surname>Yan</surname>
          <given-names>Xiaohua</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author" id="au5">
        <name>
          <surname>Huang</surname>
          <given-names>Huizhe</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author" id="au6">
        <name>
          <surname>Yang</surname>
          <given-names>Bing</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff5" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author" id="au7">
        <name>
          <surname>Zhou</surname>
          <given-names>Fangfang</given-names>
        </name>
        <email>zhoufangfang@suda.edu.cn</email>
        <xref rid="aff6" ref-type="aff">6</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <contrib contrib-type="author" id="au8">
        <name>
          <surname>Zhang</surname>
          <given-names>Long</given-names>
        </name>
        <email>L_Zhang@zju.edu.cn</email>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff7" ref-type="aff">7</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <aff id="aff1"><label>1</label>The Second Affiliated Hospital and Life Sciences Institute and School of Medicine, The MOE Key Laboratory of Biosystems Homeostasis and Protection and Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Zhejiang University, Hangzhou, China</aff>
      <aff id="aff2"><label>2</label>School of Medicine, Hangzhou City University, Hangzhou, China</aff>
      <aff id="aff3"><label>3</label>Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang, China</aff>
      <aff id="aff4"><label>4</label>The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China</aff>
      <aff id="aff5"><label>5</label>Department of Pharmaceutical Chemistry and the Cardiovascular Research Institute, University of California, San Francisco, California, USA</aff>
      <aff id="aff6"><label>6</label>Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China</aff>
      <aff id="aff7"><label>7</label>Cancer Center, Zhejiang University, Hangzhou, China</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>∗</label>For correspondence: Ran Li; Fangfang Zhou; Long Zhang <email>ranli1993@zju.edu.cn</email><email>zhoufangfang@suda.edu.cn</email><email>L_Zhang@zju.edu.cn</email></corresp>
      <fn id="fn1">
        <label>‡</label>
        <p id="ntpara0010">These authors contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>12</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>12</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <volume>23</volume>
    <issue>1</issue>
    <elocation-id>100693</elocation-id>
    <history>
      <date date-type="received">
        <day>15</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>6</day>
        <month>11</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Authors</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="abs0010">
      <p>Large-scale omics studies have generated a wealth of mass spectrometry–based proteomics data, which provide additional insights into disease biology spanning genomic boundaries. However, there is a notable lack of web-based analysis and visualization tools that facilitate the reutilization of these data. Given this challenge, we present iProPhos, a user-friendly web server to deliver interactive and customizable functionalities. iProPhos incorporates a large number of samples, including 1444 tumor samples and 746 normal samples across 12 cancer types, sourced from the Clinical Proteomic Tumor Analysis Consortium. Additionally, users can also upload their own proteomics/phosphoproteomics data for analysis and visualization. In iProPhos, users can perform profiling plotting and differential expression, patient survival, clinical feature–related, and correlation analyses, including protein–protein, mRNA-protein, and kinase-substrate correlations. Furthermore, functional enrichment, protein–protein interaction network, and kinase-substrate enrichment analyses are accessible. iProPhos displays the analytical results in interactive figures and tables with various selectable parameters. It is freely accessible at <ext-link ext-link-type="uri" xlink:href="http://longlab-zju.cn/iProPhos" id="intref0010">http://longlab-zju.cn/iProPhos</ext-link> without login requirement. We present two case studies to demonstrate that iProPhos can identify potential drug targets and upstream kinases contributing to site-specific phosphorylation. Ultimately, iProPhos allows end-users to leverage the value of big data in cancer proteomics more effectively and accelerates the discovery of novel therapeutic targets.</p>
    </abstract>
    <abstract abstract-type="graphical" id="abs0015">
      <title>Graphical Abstract</title>
      <fig id="undfig1" position="anchor">
        <graphic xlink:href="ga1"/>
      </fig>
    </abstract>
    <abstract abstract-type="author-highlights" id="abs0020">
      <title>Highlights</title>
      <p>
        <list list-type="simple" id="ulist0010">
          <list-item id="u0010">
            <label>•</label>
            <p id="p0010">iProPhos performs integrated proteome and phosphoproteome analysis.</p>
          </list-item>
          <list-item id="u0020">
            <label>•</label>
            <p id="p0020">iProPhos provides optional parameters for plotting and statistical analysis.</p>
          </list-item>
          <list-item id="u0025">
            <label>•</label>
            <p id="p0025">iProPhos allows users to upload their own data for analysis and visualization.</p>
          </list-item>
          <list-item id="u0030">
            <label>•</label>
            <p id="p0030">iProPhos can identify potential drug targets and crucial phosphorylation events.</p>
          </list-item>
        </list>
      </p>
    </abstract>
    <abstract abstract-type="teaser" id="abs0025">
      <title>In Brief</title>
      <p>We have developed iProPhos, a user-friendly web server for integrated proteome and phosphoproteome analysis using CPTAC data for 12 cancer types. iProPhos has the capability of hosting abundant analyses such as differential expression, patient survival, clinical feature–related, kinase-substrate enrichment, and correlation analyses, including protein–protein, mRNA-protein, and kinase-substrate correlations. In addition, iProPhos provides functional enrichment and PPI network analyses. We present two case studies to demonstrate that iProPhos can identify potential drug targets and upstream kinases contributing to site-specific phosphorylation.</p>
    </abstract>
    <kwd-group id="kwrds0010">
      <title>Keywords</title>
      <kwd>proteomics</kwd>
      <kwd>phosphoproteomics</kwd>
      <kwd>integrated analysis</kwd>
      <kwd>web server</kwd>
      <kwd>tumor</kwd>
    </kwd-group>
  </article-meta>
  <def-list>
    <title>Abbreviations</title>
    <def-item>
      <term id="kwrd0035">BH</term>
      <def>
        <p>Benjamini–Hochberg</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0045">CPTAC</term>
      <def>
        <p>Clinical Proteomic Tumor Analysis Consortium</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0055">GSEA</term>
      <def>
        <p>gene set enrichment analysis</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0065">HCC</term>
      <def>
        <p>hepatocellular carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0075">KSEA</term>
      <def>
        <p>kinase-substrate enrichment analysis</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0085">PPI</term>
      <def>
        <p>protein–protein interaction</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0095">PTM</term>
      <def>
        <p>posttranslational modification</p>
      </def>
    </def-item>
    <def-item>
      <term id="kwrd0105">TMT</term>
      <def>
        <p>tandem mass tag</p>
      </def>
    </def-item>
  </def-list>
</front>
<body>
  <p id="p0035">Proteins execute various biological processes and carry biological information not accessible through genomics or transcriptomics (<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>). Protein phosphorylation is one of the most common and essential posttranslational modifications (PTMs) in biological systems, considerably affecting protein function, stability, and interactions with other cellular components (<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>). Weak or negative correlations between mRNA and protein abundance in certain genes hinder gene function predictions using transcriptomic data (<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>). With advancements in high-throughput technologies, MS-based proteomics has become a powerful tool in functional research (<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>). Large consortium projects, such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), have generated a tremendous amount of proteomic data. However, analyzing and mining these data require proficient programming skills, making proteomics analysis and visualization a considerable challenge for experimental and clinical personnel.</p>
  <p id="p0040">To date, several tools have been developed for proteomics analysis, including TCPA (<xref rid="bib12" ref-type="bibr">12</xref>), CPPA (<xref rid="bib13" ref-type="bibr">13</xref>), UALCAN (<xref rid="bib14" ref-type="bibr">14</xref>) and LinkedOmics (<xref rid="bib15" ref-type="bibr">15</xref>), but they offer a limited range of analytical types. TCPA is a web-based resource for accessing, analyzing, and visualizing cancer functional proteomics. However, it only encompasses approximately 300 reverse phase protein array–based protein markers and lacks normal samples for differential expression analysis. CPPA is an interactive web server for mining the characteristics of proteins and protein phosphorylation, but it cannot perform integrated analysis between proteomics and phosphoproteomics data. UALCAN and LinkedOmics are designed for the integrative analysis of multiomics data. However, UALCAN can only conduct differential expression analysis for proteomics data, while LinkedOmics focuses on exploring associations between different types of attributes, and lacks the capability to identify differentially expressed proteins in tumors and perform functional enrichment analysis for them. Furthermore, TCPA, CPPA, and UALCAN do not support functional enrichment analysis and cannot evaluate the correlation between mRNA and protein abundance. None of these tools provide kinase-substrate correlation analysis or protein–protein interaction (PPI) network analysis. More importantly, none of them allow users to upload their own proteomics/phosphoproteomics data for analysis, and customized options for analyzing and visualizing data are limited.</p>
  <p id="p0045">To address the issues with the current proteomics data analysis tools, we have developed iProPhos, a user-friendly web server for integrated proteome and phosphoproteome analysis using CPTAC data for 12 cancer types, comprising 1444 tumor samples and 746 normal samples (<xref rid="appsec1" ref-type="sec">supplemental Table S1</xref>). Furthermore, iProPhos allows users to upload their preprocessed proteomics/phosphoproteomics data for analysis and visualization. iProPhos has “Proteome Analysis” and “Phosphoproteome Analysis” modules (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). These modules perform similar functions for differential analysis, survival analysis and clinical feature-related analyses (including age, gender, and tumor stage). In the “Proteome Analysis” module, iProPhos performs functional enrichment analysis on proteins of interest and incorporates transcriptomics data paired with proteomics data for each sample to conduct correlation analysis between mRNA and protein abundance. In the “Phosphoproteome Analysis” module, iProPhos can infer kinase activity changes in tumors and integrate proteomics and phosphoproteomics data for correlation analysis. Moreover, iProPhos allows users to customize the analytic parameters, graphic color, and point size. <xref rid="tbl1" ref-type="table">Table 1</xref> compares the key features of iProPhos with those of the other available tools. Overall, iProPhos overcomes the limitations of existing proteomics analysis tools by integrating proteomics with transcriptomics or phosphoproteomics, providing downstream functional enrichment analysis and PPI network analysis, as well as customized data visualization options. These distinguishing features considerably broaden the scope of applications of iProPhos.<fig id="fig1"><label>Fig. 1</label><caption><p><bold>Schematic of iProPhos.</bold> iProPhos collected the omics data from the CPTAC project. All datasets were uniformly processed with a standardized workflow. iProPhos also allows users to upload their preprocessed data for analysis. iProPhos has analysis modules including “Proteome Analysis” and “Phosphoproteome Analysis,” as well as their integrated analysis. The <italic>bottom part</italic> shows the representative outputs of each module. iProPhos allows users to customize graphic parameters and statistical methods. CPTAC, Clinical Proteomic Tumor Analysis Consortium; FC, fold change; GSEA, gene set enrichment analysis; ORA, over-representation analysis; PPI, protein–protein interaction.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Comparison of iProPhos with existing web servers</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Feature</th><th>TCPA</th><th>CPPA</th><th>UALCN</th><th>LinkedOmics</th><th>iProPhos</th></tr></thead><tbody><tr><td>Data type</td><td>RPPA- based</td><td>MS-based</td><td>MS-based</td><td>RPPA- and MS-based</td><td>MS-based</td></tr><tr><td>Differential expression analysis</td><td>-</td><td>√</td><td>√</td><td>-</td><td>√</td></tr><tr><td>Functional enrichment analysis</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>PPI network analysis</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>mRNA-protein correlation</td><td>-</td><td>-</td><td>-</td><td>√</td><td>√</td></tr><tr><td>Survival analysis</td><td>√</td><td>√</td><td>-</td><td>√</td><td>√</td></tr><tr><td>Kinase-substrate correlation</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>Clinical features–related analysis</td><td>√</td><td>√</td><td>-</td><td>√</td><td>√</td></tr><tr><td>User upload</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr><tr><td>Customized options</td><td>-</td><td>-</td><td>-</td><td>-</td><td>√</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Symbols used for feature evaluations with “√” for present, “-”for absent. The URLs for each tool are given below.</p></fn><fn id="tspara0020"><p>TCPA: <ext-link ext-link-type="uri" xlink:href="https://www.tcpaportal.org/tcpa/" id="intref0045">https://www.tcpaportal.org/tcpa/</ext-link>.</p></fn><fn id="tspara0025"><p>CPPA: <ext-link ext-link-type="uri" xlink:href="http://cppa.site/cppa/" id="intref0050">http://cppa.site/cppa/</ext-link>.</p></fn><fn id="tspara0030"><p>UALCAN: <ext-link ext-link-type="uri" xlink:href="https://ualcan.path.uab.edu/" id="intref0055">https://ualcan.path.uab.edu/</ext-link>.</p></fn><fn id="tspara0035"><p>LinkedOmics: <ext-link ext-link-type="uri" xlink:href="http://linkedomics.org/" id="intref0060">http://linkedomics.org/</ext-link>.</p></fn><fn id="tspara0040"><p>iProPhos: <ext-link ext-link-type="uri" xlink:href="http://longlab-zju.cn/iProPhos/" id="intref0065">http://longlab-zju.cn/iProPhos/</ext-link>.</p></fn><fn id="tspara0045"><p>Abbreviations: MS, mass spectrometry; RPPA, reverse phase protein array.</p></fn></table-wrap-foot></table-wrap></p>
  <p id="p0050">To test iProPhos and demonstrate its capabilities, we presented two case studies and showed that iProPhos had good performance in investigating potential drug targets and revealing crucial phosphosites and their upstream kinases. In summary, iProPhos can provide new insights into the mechanisms underlying cancer progression and facilitate the exploration of novel therapeutic strategies for researchers.</p>
  <sec id="sec1">
    <title>Experimental Procedures</title>
    <sec id="sec1.1">
      <title>Data Collection</title>
      <p id="p0055">Transcriptome, proteome, phosphoproteome, and clinical characteristic data of 12 cancer types were sourced from the CPTAC data portal (<ext-link ext-link-type="uri" xlink:href="https://proteomic.datacommons.cancer.gov/pdc/" id="intref0015">https://proteomic.datacommons.cancer.gov/pdc/</ext-link>) (<xref rid="bib16" ref-type="bibr">16</xref>). The expression levels of the transcripts were quantified using the normalized metric, FPKM-UQ (<ext-link ext-link-type="uri" xlink:href="https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/Expression_mRNA_Pipeline/" id="intref0020">https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/Expression_mRNA_Pipeline/</ext-link>). Protein abundance and phosphorylation levels were uniformly processed using the common data analysis pipeline (<xref rid="bib17" ref-type="bibr">17</xref>). Clinical characteristics included age, gender, tumor stage, survival status, and survival time. In addition, we collected proteomics and phosphoproteomics data from matched normal samples, as well as transcriptomics data paired with proteomics data from tumor samples.</p>
    </sec>
    <sec id="sec1.2">
      <title>Data Preprocessing</title>
      <p id="p0060">For the transcriptomics data, we centered and scaled the normalized gene expression data to generate standardized expression values (z-scores). In the proteomics data, we filtered proteins with more than 50% missing values across samples and imputed missing values using KNN algorithm implemented in the R package impute. The principles of the filter and imputation method for missing values were also applied to the phosphoproteomics data. Proteomics and phosphoproteomics data were tandem mass tag–based, and the relative abundances of proteins or phosphosites are presented as log2 tandem mass tag ratios with the median centering.</p>
    </sec>
    <sec id="sec1.3">
      <title>Implementation</title>
      <p id="p0065">The iProPhos web server is freely available to all users without login requirement for access. We built it on the R Shiny framework, using the HTML5, CSS, and Shiny JavaScript (shinyjs) libraries for rendering and interactive operations of front-end pages. The user interface layout is organized with a sidebar containing widgets for target inputs and options for analysis and visualization. The main panel displays the outputs in plot or table formats. Interactive tables were generated using the R package DT (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/DT/index.html" id="PC_linkjU1sp757lb">https://cran.r-project.org/web/packages/DT/index.html</ext-link>) to facilitate efficient data querying and selection. All outputs are available for download, with plots saved in PDF format as editable vector graphics compatible with vector graphic editors, such as Adobe Illustrator. iProPhos has been successfully tested on several browsers, including Google Chrome, Firefox, Internet Explorer (version 10 or later), and Safari. The R packages used in the web server are listed in <xref rid="appsec1" ref-type="sec">supplemental Table S2</xref>.</p>
    </sec>
  </sec>
  <sec id="sec2">
    <title>Results</title>
    <sec id="sec2.1">
      <title>iProPhos Performs Proteomics-Related Analyses</title>
      <p id="p0070">iProPhos can perform proteomics-related analyses and integrates transcriptomics data to investigate the complex relationships between gene expression and protein abundance in biological systems.</p>
      <p id="p0075">Differentially expressed proteins between tumor and normal samples drive tumorigenesis and progression. iProPhos conducts differential expression analysis using two approaches and presents the results with box plots and volcano plots (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>A</italic>). For the box plots, users can choose <italic>t</italic> test, Wilcoxon test, or ANOVA methods for hypothesis testing to evaluate the differences between two groups of samples. The <italic>t</italic> test is two-tailed and assumes unequal variances, and the Wilcoxon test is a Wilcoxon rank-sum test. The box color and point size are customizable. For the volcano plots, iProPhos fits a linear model to calculate the fold change and statistical significance of proteins using the R package limma (<xref rid="bib18" ref-type="bibr">18</xref>). Users can also set the cutoff value to define significance. Upregulated and downregulated proteins in tumor samples are labeled orange and blue respectively, whereas gray indicates nonsignificance. Moreover, a protein of interest can be magnified and highlighted with its gene symbol. The interactive table is displayed under a volcano plot containing the fold change and statistical significance data.<fig id="fig2"><label>Fig. 2</label><caption><p><bold>Proteome analysis module of iProPhos.</bold><italic>A</italic>, iProPhos presents differential expression analysis results with <italic>boxplots</italic> or <italic>volcano plots</italic>. <italic>B</italic>, the <italic>scatter plot</italic> illustrates the correlation between the abundance of two interested proteins, and the table displays the correlation of the abundance of one interested protein with the other detectable proteins in a given tumor type. <italic>C</italic>, Kaplan–Meier curves for overall survival. Patients are grouped based on the abundance of the protein of interest. <italic>D</italic>, iProPhos provides correlation analysis between mRNA and protein abundance. <italic>E</italic>–<italic>G</italic>, iProPhos provides clinical feature–related analysis for protein abundance, including age (<italic>E</italic>), gender (<italic>F</italic>), and tumor stage (<italic>G</italic>). <italic>H</italic>, iProPhos presents gene ontology (GO) enrichment analysis results with <italic>bar plots</italic> or <italic>dot plots</italic>. <italic>I</italic>, iProPhos presents Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analysis results with <italic>bar plots</italic> or <italic>dot plots</italic>. <italic>J</italic>, iProPhos can perform GSEA analysis for the target gene set. <italic>K</italic>, the PPI network map of proteins of interest. BP, biological process; CC, cell component; GSEA, gene set enrichment analysis; MF, molecular function; PPI, protein–protein interaction.</p></caption><graphic xlink:href="gr2"/></fig></p>
      <p id="p0080">Correlation analysis is essential for evaluating cooperative relationships between any two proteins. iProPhos delivers correlation results in the form of scatter plots or tables (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>B</italic>), allowing users to explore protein correlations conveniently. In the “Correlation Plot” tab panel, users can investigate correlations between two proteins of interest in a specific tumor and customize various graphic parameters (such as point size and color) and correlation measuring methods (<italic>e.g.</italic>, Pearson, Spearman, and Kendall correlations). In the “Correlation Table” tab panel, users can investigate correlations of the target protein with other proteins to gain biological ideas for further study.</p>
      <p id="p0085">Survival analysis can associate protein abundance with clinical outcomes and provide valuable insights for selecting potential drug targets. iProPhos provides two methods for calculating the cut-off value that divides patients into two groups. One method is to set the median value of protein abundance as the cutoff point, and the other is to utilize the surv_cutpoint algorithm applied in the R package survminer to determine the optimal cut-off point. The colors for these two groups are also customizable. iProPhos outputs Kaplan–Meier survival curves with log-rank <italic>p</italic> values and 95% confidence intervals (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>C</italic>).</p>
      <p id="p0090">Proteins are functionally relevant to phenotypes. However, the extent to which protein abundance correlates with the mRNA level and whether this correlation breaks down in some genes are not fully understood. mRNA-protein correlation analysis can refine our understanding of the principles of gene expression control in tumor cells (<xref rid="bib19" ref-type="bibr">19</xref>). iProPhos can perform correlation analysis between given mRNA and protein in the specific cancer type (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>D</italic>). The point size, color, and analysis methods are customizable.</p>
      <p id="p0095">iProPhos can investigate associations between protein abundance and clinical features, such as age, gender, and tumor stage (<xref rid="fig2" ref-type="fig">Fig. 2</xref>, <italic>E</italic>–<italic>G</italic>), which are crucial for identifying potential prognostic biomarkers and advancing personalized medicine. For age-relevant analysis, iProPhos allows users to choose the patients’ median age or to input a suitable number as the cutoff value. These analyses output the results with violin plots. The methods for differential analysis are optional, except for tumor stage-related analysis, where one-way ANOVA is required.</p>
      <p id="p0100">Enrichment analysis focuses on gene sets that share common biological attributes, helping researchers identify dysregulated pathways and generate hypothesises (<xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>). iProPhos performs over-representation analysis and gene set enrichment analysis (GSEA) using the R package clusterProfiler (<xref rid="bib22" ref-type="bibr">22</xref>). For over-representation analysis analysis, users can set a cut-off value to define differentially upregulated or downregulated proteins. Then functional enrichment analysis is performed based on Gene Ontology (<xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>) or Kyoto Encyclopedia of Genes and Genomes (<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>) annotations. Redundant Gene Ontology terms are removed using “simplify” method to present the most informative terms. The results are output in the table format and displayed with bar plots and dot plots (<xref rid="fig2" ref-type="fig">Fig. 2, H and I</xref>). For GSEA analysis, users can input the gene list of interest and rank genes based on the fold change from the differential expression analysis. The GSEA result is shown graphically, along with statistical significance (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>J</italic>).</p>
      <p id="p0105">PPI networks represent the relationships between proteins that are crucial for deciphering the mechanisms of cellular processes and diseases. iProPhos performs PPI network analysis using the R package stringdb (<xref rid="bib27" ref-type="bibr">27</xref>). Users can customize the cut-off value to define proteins for network analysis. iProPhos also generates an interactive network diagram of protein interactions (including both physical and functional interactions) (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic>K</italic>). Nodes represent proteins, and edges represent their interactions, with thicker edges indicating a higher confidence of interactions. Additionally, users can download the results in tabular format for further analysis in Cytoscape (<ext-link ext-link-type="uri" xlink:href="https://cytoscape.org/" id="PC_linkGCNF8L3jHq">https://cytoscape.org/</ext-link>) or other similar software.</p>
    </sec>
    <sec id="sec2.2">
      <title>iProPhos Performs Phosphoproteomics-Related Analyses</title>
      <p id="p0110">iProPhos can perform phosphoproteomics-related analyses and integrate with proteomics data, gaining insights into the aberrant phosphorylation events associated with tumorigenesis and progression. The clinical feature-related analysis for phosphorylation level, including age, gender, and tumor stage (<xref rid="fig3" ref-type="fig">Fig. 3</xref>, <italic>A</italic>–<italic>C</italic>), and differential analysis comparing phosphorylation level of phosphosites between tumor and normal samples (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>D</italic>), are the same as those in the “Proteome Analysis” module. Therefore, these features are not repeated here.<fig id="fig3"><label>Fig. 3</label><caption><p><bold>Phosphoproteome analysis module of iProPhos.</bold><italic>A</italic>–<italic>C</italic>, iProPhos provides clinical feature–related analysis for phosphorylation level, including age (<italic>A</italic>), gender (<italic>B</italic>), and tumor stage (<italic>C</italic>). <italic>D</italic>, iProPhos presents differential phosphorylation level analysis results with <italic>boxplots</italic> or <italic>volcano plots</italic>. <italic>E</italic>, iProPhos provides correlation analysis between protein abundance and the phosphorylation level of the specific phosphosite. <italic>F</italic>, iProPhos conducts correlation analysis between protein abundance of kinases and phosphorylation levels of substrates. <italic>G</italic>, iProPhos estimates the changes in kinase activities in tumor samples compared to normal samples. The <italic>bar pl</italic>ot shows the normalized score for each kinase (z-score), weighted by the number of identified substrates. <italic>Red</italic> means significant activation in tumors, <italic>blue</italic> represents significant inactivation, and <italic>black</italic> denotes kinases with nonsignificant scores; the kinase scores table lists enrichment scores of all kinases; kinase-substrate links table shows the kinase and substrate relationships collected from the selected dataset. <italic>H</italic>, iProPhos performs overall survival analysis based on the phosphorylation level. The table shows the survival analysis results for all detected phosphosites of a given protein; Kaplan–Meier curves show the survival analysis result for a certain phosphosite. The statistical significance is determined by log-rank test.</p></caption><graphic xlink:href="gr3"/></fig></p>
      <p id="p0115">Studying the correlation between protein abundance and the phosphorylation levels of phosphosites provides new insights into the regulatory networks and mechanisms driving tumor progression. iProPhos can evaluate the correlation not only between proteins and their phosphosites but also between proteins and phosphosites on different proteins (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>E</italic>).</p>
      <p id="p0120">The abundance of some kinases correlates with their known substrate phosphorylation levels (<italic>e.g.</italic>, CDK1, CDK2) (<xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>). iProPhos can investigate correlations between the protein abundance of kinases and the phosphorylation levels of substrates. The results are presented with the table consisting of kinase-substrate links and the corresponding correlation coefficient and <italic>p</italic> value (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>F</italic>). These analyses can provide potential kinase-substrate pairs and reveal the complexity of signaling pathways and networks. The kinase list was collected from PhosphoSitePlus (<xref rid="bib30" ref-type="bibr">30</xref>) (<ext-link ext-link-type="uri" xlink:href="http://www.phosphosite.org" id="intref0025">http://www.phosphosite.org</ext-link>), a well-established resource containing expert-curated annotations, and NetworKIN (<xref rid="bib31" ref-type="bibr">31</xref>) (<ext-link ext-link-type="uri" xlink:href="https://networkin.info/" id="intref0030">https://networkin.info/</ext-link>), which consists of predicted kinase-substrate relationships obtained by integrating various data sources, including sequence-based predictions, experimental kinase-substrate relationships, and PPI networks.</p>
      <p id="p0125">iProPhos can estimate changes in kinase activity based on collective phosphorylation changes of identified substrates using the kinase-substrate enrichment analysis (KSEA) algorithm (<xref rid="bib32" ref-type="bibr">32</xref>). Differential phosphorylation analysis is performed between tumor and normal samples for a given tumor type using the R package limma, and the results are analyzed using the KSEA module. Users can choose the data sources of the kinase-substrate relationship. Among them, PhosphoSitePlus includes only experimentally verified kinase-substrate relationships, which is recommended for more conservative results. In contrast, NetworKIN provides the predicted relationships. iProPhos presents the results with graphic and tabular formats (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>G</italic>). The kinase scores are displayed with bar plots; kinases labeled red are predicted to be significantly activated in tumors, kinases labeled blue are predicted to be significantly inactivated, and black indicates nonsignificance. The list of kinase scores provides the enrichment scores of kinases with at least one identified substrate in the selected dataset, and the list of kinase-substrate links provides the kinase-substrate relationships collected from the selected dataset.</p>
      <p id="p0130">Exploring the correlation between phosphorylation levels and clinical outcomes is valuable for further studies. iProPhos generates a convenient table that provides survival analysis results for all detected phosphosites in a given protein (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>H</italic>). Using this function, users can easily select phosphosites that significantly correlate with survival outcomes. iProPhos provides the Kaplan–Meier survival curve plot using the log-rank test (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic>H</italic>). The grouping methods and colors are customizable.</p>
    </sec>
    <sec id="sec2.3">
      <title>iProPhos can Identify Potential Drug Targets</title>
      <p id="p0135">Proteomics data provide an excellent opportunity to identify candidate proteins for future clinical treatments, potentially leading to beneficial outcomes. iProPhos has the ability to screen candidate targets. Take the instance of pancreatic ductal adenocarcinoma, which is a highly aggressive malignancy with the low survival rate (<xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>). First, we conducted differential expression analysis between tumor and normal samples using the limma algorithm based on protein abundance. To control the false discovery rate, we used Benjamini–Hochberg (BH) correction for all proteins and the same correction applies to all results in this article. Second, the Food and Drug Administration approved or candidate drug targets were extracted from the Human Protein Atlas. Overlapping proteins between drug targets and differentially expressed proteins (BH adjusted <italic>p</italic> &lt; 0.05) were selected for further analysis. Then, we focused on two proteins, PIEZO1 and PLAU, which were significantly upregulated in tumors (<xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>A</italic> and <italic>B</italic>). PIEZO1 is a mechanosensitive ion channel, which transduces various mechanical stimulations into electrochemical signals (<xref rid="bib35" ref-type="bibr">35</xref>), and PLAU is a serine protease, which promotes fibrinolysis and degradation of extracellular matrix (<xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>). In addition, we also employed the Wilcoxon test to validate the differences in protein abundance (PIEZO1, BH adjusted <italic>p</italic> = 1.3e-04; PLAU, BH adjusted <italic>p</italic> = 1.6e-22; <xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>C</italic> and <italic>D</italic>). Furthermore, we performed survival analysis to investigate the possibility of these two proteins as drug targets. Based on the optimal cut-off point, we classified patients into high- and low-expression groups and found a significant survival difference between them. The high-expression group exhibited a poorer survival outcome than the low-expression group (log-rank test, BH adjusted <italic>p</italic> = 0.027, and BH adjusted <italic>p</italic> = 0.014 for PIEZO1 and PLAU, respectively; <xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>E</italic> and <italic>F</italic>). Moreover, we found that PLAU genes exhibited significantly positive correlation between mRNA expression and its protein abundance, while PIEZO1 showed a weaker correlation (R = 0.75, BH adjusted <italic>p</italic> = 4.5e-24 for PLAU; R = 0.24, BH adjusted <italic>p</italic> = 7.7e-03 for PIEZO1; <xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic>G</italic> and <italic>H</italic>). These findings highlight the importance of direct exploration of protein expression profiles, as relying solely on mRNA expression may overlook the critical information regarding protein regulation and function.<fig id="fig4"><label>Fig. 4</label><caption><p><bold>iProPhos could reveal potential drug targets and infer crucial phosphosites and their upstream kinases.</bold><italic>A</italic> and <italic>B</italic>, <italic>volcano plots</italic> show that PIEZO1 (<italic>A</italic>) and PLAU (<italic>B</italic>) are significantly upregulated in PDA (Benjamini–Hochberg [BH] adjusted <italic>p</italic> &lt; 0.05). <italic>C</italic> and <italic>D</italic>, PIEZO1 (<italic>C</italic>) and PLAU (<italic>D</italic>) show significantly higher expression in PDA. <italic>E</italic> and <italic>F</italic>, survival analysis of PDA patients based on the protein abundance of PIEZO1 (<italic>E</italic>) and PLAU (<italic>F</italic>). <italic>G</italic> and <italic>H</italic>, Pearson’s correlation analysis between mRNA and protein abundance of PIEZO1 (<italic>G</italic>) and PLAU (<italic>H</italic>). <italic>I</italic>, evaluation of kinase activity changes by kinase-substrate enrichment analysis in HCC. <italic>Red</italic> means significant activation in tumors, <italic>blue</italic> represents significant inactivation, and <italic>black</italic> denotes kinases with nonsignificant scores. <italic>J</italic>, Pearson’s correlation analysis between CDK1 abundance and the phosphorylation level of NCL-S67. <italic>K</italic>, <italic>boxplot</italic> shows that phosphorylation level of NCL-S67 is significantly upregulated in HCC. <italic>L</italic>, survival analysis of HCC patients based on the phosphorylation level of NCL-S67. HCC, hepatocellular carcinoma; PDA, pancreatic ductal adenocarcinoma.</p></caption><graphic xlink:href="gr4"/></fig></p>
      <p id="p0140">In summary, iProPhos is a valuable tool that enables researchers to conveniently explore cancer proteomics and identify potential drug targets.</p>
    </sec>
    <sec id="sec2.4">
      <title>iProPhos can Identify Crucial Phosphosites and Their Upstream Kinases</title>
      <p id="p0145">The identification of kinase-substrate relationships is crucial for understanding phosphorylation signals. Take the example of hepatocellular carcinoma (HCC), iProPhos inferred kinase activity changes using the KSEA method. Kinase-substrate annotations were obtained from PhosphoSitePlus and NetworKIN, and the NetworkKIN score cut-off was set to 8. Results showed a significant upregulation of the activity of CSNK2A1, CDK1, PLK1, PRKDC, and CDK2 in HCC (<xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>I</italic> and <xref rid="appsec1" ref-type="sec">supplemental Table S3</xref>). CDK1 plays a critical role in cell cycle progression, and the overactivation of CDK1 has been identified to be closely associated with tumorigenesis (<xref rid="bib38" ref-type="bibr">38</xref>). NCL-S67 was inferred to be the substrate of CDK1 (<xref rid="appsec1" ref-type="sec">supplemental Table S4</xref>). We further investigated the correlation between the protein abundance of CDK1 and the phosphorylation level of NCL-S67. The results demonstrated a significantly positive correlation between them (R = 0.81, BH adjusted <italic>p</italic> = 3.3e-25; <xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>J</italic>). We also found that the phosphorylation level of NCL-S67 was significantly upregulated in HCC compared with matched normal samples (Wilcoxon test, BH adjusted <italic>p</italic> = 2.1e-37; <xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>K</italic>). Next, we performed survival analysis using the median phosphorylation level of NCL-S67 as the cut-off value, finding that the high-expression group had a worse prognosis (log-rank test, BH adjusted <italic>p</italic> = 1.8e-03; <xref rid="fig4" ref-type="fig">Fig. 4</xref><italic>L</italic>). These results demonstrate that iProPhos is a powerful tool for discovering critical phosphorylation events, which can ultimately improve our understanding of disease biology.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Discussion</title>
    <p id="p0150">Mass spectrometry–based proteomics is a widely effective method for identifying, characterizing, and quantifying proteins. Proteins play an indispensable role in biological processes, and PTMs of proteins can regulate the biological functions of cells. The presence of PTMs increases the chemical diversity and complexity of the proteins, making comprehensive analysis of proteomics crucial for understanding cancer biology. However, genomics and transcriptomics methods fail to capture information about PTMs, making proteomics the sole approach for large-scale study of these modifications.</p>
    <p id="p0155">In high-throughput proteomics, analyzing and interpreting quantitative results to propose biological or clinical hypotheses is an ongoing challenge. Currently, there is a scarcity of comprehensive analysis and visualization tools for proteomics data, particularly in phosphoproteomics. Therefore, we have developed iProPhos, a user-friendly web server that provides a comprehensive and integrated analysis platform for proteome and phosphoproteome data. iProPhos can not only separately explore proteomics/phosphoproteomics differences between sample groups, but also integrate proteomics with transcriptomics or phosphoproteomics. iProPhos has the competency of hosting more abundant analyses such as differential expression, patient survival, clinical feature-related, kinase-substrate enrichment, and correlation analyses, including protein–protein, mRNA-protein, and kinase-substrate correlations. In addition, iProPhos provides downstream functional enrichment analysis and PPI network analysis, enabling researchers to gain deeper insights into the functional implications and interactions of the proteins of interest. The extensive analyses provided by iProPhos, accessible with only a few clicks, enable researchers without programming skills to perform multiple analyses. Moreover, iProPhos provides a series of optional parameters for plotting and statistical analysis, helping generate publication-ready figures.</p>
    <p id="p0160">Most existing analysis tools focus on the transcriptome, but protein and mRNA levels exhibit discrepancies in certain genes (<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>). A previous study explored mRNA-protein correlations across 32 normal human tissues for each gene, finding that the median Spearman correlation was 0.46 (<xref rid="bib41" ref-type="bibr">41</xref>). It is suggested that proteomics data provide additional information missing in transcriptomic studies, facilitating a more comprehensive understanding of tumor development and the discovery of novel therapeutic strategies. Moreover, phosphoproteomics studies and their integrated analysis with proteomics data further enrich the breadth of the study, enabling the exploration of critical phosphorylation events and kinase-substrate relationships, which fill the gaps in a single-layer analysis and enhance our understanding of the molecular mechanisms underlying the disease.</p>
    <p id="p0165">Due to the limitation of available datasets integrating transcriptome, proteome, and phosphoproteome, iProPhos has collected omics data from only 12 cancer types. In the future, we will continue to incorporate more tumor proteomics datasets, including different cancer types. Moreover, we consider integrating proteomics data from various cancer cell lines in the next version, as these models provide valuable insights into understanding cellular processes and the underlying factors driving carcinogenesis. iProPhos currently provides correlation analysis for paired proteins, but it cannot identify biological networks based on pairwise correlations. In future iterations, iProPhos will provide weighted gene coexpression network analysis to find highly correlated protein clusters and identify hub proteins within those clusters. Furthermore, iProPhos will utilize advanced machine learning algorithms to enhance the efficiency and accuracy of biomarker identification. iProPho will be updated continuously and provide researchers with a powerful tool for studying the role of proteins and PTMs in tumor progression and further leveraging the value of big data in cancer proteomics.</p>
    <p id="p0170">In summary, iProPhos is an intuitive and time-saving tool for the cancer community to dissect oncogenic signaling networks and address unmet clinical needs. Its comprehensive analysis capabilities, integration of different omics data, and potential for biomarker identification make it a valuable asset to unravel the complexities of cancer biology and develop novel therapeutic interventions.</p>
  </sec>
  <sec sec-type="data-availability" id="sec4">
    <title>Data Availability</title>
    <p id="p0175">iProPhos is free and open to all users, with no login requirement. Transcriptome, proteome, phosphoproteome, and clinical data across 12 cancer types were sourced from the CPTAC data portal (<ext-link ext-link-type="uri" xlink:href="https://proteomic.datacommons.cancer.gov/pdc/" id="intref0035">https://proteomic.datacommons.cancer.gov/pdc/</ext-link>). The code for producing iProPhos will be deposited to GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/longLabzj/iProPhos/" id="intref0040">https://github.com/longLabzj/iProPhos/</ext-link>), and will be publicly available upon publication.</p>
  </sec>
  <sec sec-type="supplementary-material" id="sec5">
    <title>Supplemental Data</title>
    <p id="p0180">This article contains <xref rid="appsec1" ref-type="sec">supplemental data</xref>.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p id="p0185">The authors declare no competing interests.</p>
  </sec>
</body>
<back>
  <ref-list id="cebib0010">
    <title>References</title>
    <ref id="bib1">
      <label>1</label>
      <element-citation publication-type="journal" id="sref1">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>Yaffe</surname>
            <given-names>M.B.</given-names>
          </name>
        </person-group>
        <article-title>Protein regulation in signal transduction</article-title>
        <source>Cold Spring Harb. Perspect. Biol.</source>
        <volume>8</volume>
        <year>2016</year>
        <object-id pub-id-type="publisher-id">a005918</object-id>
      </element-citation>
    </ref>
    <ref id="bib2">
      <label>2</label>
      <element-citation publication-type="journal" id="sref2">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Tong</surname>
            <given-names>R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials</article-title>
        <source>Signal. Transduct. Target. Ther.</source>
        <volume>5</volume>
        <year>2020</year>
        <fpage>213</fpage>
        <pub-id pub-id-type="pmid">32968059</pub-id>
      </element-citation>
    </ref>
    <ref id="bib3">
      <label>3</label>
      <element-citation publication-type="journal" id="sref3">
        <person-group person-group-type="author">
          <name>
            <surname>Timp</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Timp</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>Beyond mass spectrometry, the next step in proteomics</article-title>
        <source>Sci. Adv.</source>
        <volume>6</volume>
        <year>2020</year>
        <object-id pub-id-type="publisher-id">eaax8978</object-id>
      </element-citation>
    </ref>
    <ref id="bib4">
      <label>4</label>
      <element-citation publication-type="journal" id="sref4">
        <person-group person-group-type="author">
          <name>
            <surname>Bilbrough</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Piemontese</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Seitz</surname>
            <given-names>O.</given-names>
          </name>
        </person-group>
        <article-title>Dissecting the role of protein phosphorylation: a chemical biology toolbox</article-title>
        <source>Chem. Soc. Rev.</source>
        <volume>51</volume>
        <year>2022</year>
        <fpage>5691</fpage>
        <lpage>5730</lpage>
        <pub-id pub-id-type="pmid">35726784</pub-id>
      </element-citation>
    </ref>
    <ref id="bib5">
      <label>5</label>
      <element-citation publication-type="journal" id="sref5">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>Z.H.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z.Y.</given-names>
          </name>
        </person-group>
        <article-title>Regulatory mechanisms and novel therapeutic targeting strategies for protein tyrosine phosphatases</article-title>
        <source>Chem. Rev.</source>
        <volume>118</volume>
        <year>2018</year>
        <fpage>1069</fpage>
        <lpage>1091</lpage>
        <pub-id pub-id-type="pmid">28541680</pub-id>
      </element-citation>
    </ref>
    <ref id="bib6">
      <label>6</label>
      <element-citation publication-type="journal" id="sref6">
        <person-group person-group-type="author">
          <name>
            <surname>Hunter</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling</article-title>
        <source>Cell</source>
        <volume>80</volume>
        <year>1995</year>
        <fpage>225</fpage>
        <lpage>236</lpage>
        <pub-id pub-id-type="pmid">7834742</pub-id>
      </element-citation>
    </ref>
    <ref id="bib7">
      <label>7</label>
      <element-citation publication-type="journal" id="sref7">
        <person-group person-group-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>E.C.B.</given-names>
          </name>
          <name>
            <surname>Carter</surname>
            <given-names>E.K.</given-names>
          </name>
          <name>
            <surname>Dammer</surname>
            <given-names>E.B.</given-names>
          </name>
          <name>
            <surname>Duong</surname>
            <given-names>D.M.</given-names>
          </name>
          <name>
            <surname>Gerasimov</surname>
            <given-names>E.S.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level</article-title>
        <source>Nat. Neurosci.</source>
        <volume>25</volume>
        <year>2022</year>
        <fpage>213</fpage>
        <lpage>225</lpage>
        <pub-id pub-id-type="pmid">35115731</pub-id>
      </element-citation>
    </ref>
    <ref id="bib8">
      <label>8</label>
      <element-citation publication-type="journal" id="sref8">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Beyer</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Aebersold</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>On the dependency of cellular protein levels on mRNA abundance</article-title>
        <source>Cell</source>
        <volume>165</volume>
        <year>2016</year>
        <fpage>535</fpage>
        <lpage>550</lpage>
        <pub-id pub-id-type="pmid">27104977</pub-id>
      </element-citation>
    </ref>
    <ref id="bib9">
      <label>9</label>
      <element-citation publication-type="journal" id="sref9">
        <person-group person-group-type="author">
          <name>
            <surname>Giudice</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Petsalaki</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>Proteomics and phosphoproteomics in precision medicine: applications and challenges</article-title>
        <source>Brief. Bioinform.</source>
        <volume>20</volume>
        <year>2019</year>
        <fpage>767</fpage>
        <lpage>777</lpage>
        <pub-id pub-id-type="pmid">29077858</pub-id>
      </element-citation>
    </ref>
    <ref id="bib10">
      <label>10</label>
      <element-citation publication-type="journal" id="sref10">
        <person-group person-group-type="author">
          <name>
            <surname>Aebersold</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Mann</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Mass spectrometry-based proteomics</article-title>
        <source>Nature</source>
        <volume>422</volume>
        <year>2003</year>
        <fpage>198</fpage>
        <lpage>207</lpage>
        <pub-id pub-id-type="pmid">12634793</pub-id>
      </element-citation>
    </ref>
    <ref id="bib11">
      <label>11</label>
      <element-citation publication-type="journal" id="sref11">
        <person-group person-group-type="author">
          <name>
            <surname>Meissner</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Geddes-McAlister</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mann</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bantscheff</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>The emerging role of mass spectrometry-based proteomics in drug discovery</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <volume>21</volume>
        <year>2022</year>
        <fpage>637</fpage>
        <lpage>654</lpage>
        <pub-id pub-id-type="pmid">35351998</pub-id>
      </element-citation>
    </ref>
    <ref id="bib12">
      <label>12</label>
      <element-citation publication-type="journal" id="sref12">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Akbani</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Ju</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Roebuck</surname>
            <given-names>P.L.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TCPA: a resource for cancer functional proteomics data</article-title>
        <source>Nat. Methods</source>
        <volume>10</volume>
        <year>2013</year>
        <fpage>1046</fpage>
        <lpage>1047</lpage>
      </element-citation>
    </ref>
    <ref id="bib13">
      <label>13</label>
      <element-citation publication-type="journal" id="sref13">
        <person-group person-group-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>G.S.</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>Z.Z.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>Y.H.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>D.C.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>CPPA: a web tool for exploring proteomic and phosphoproteomic data in cancer</article-title>
        <source>J. Proteome Res.</source>
        <volume>22</volume>
        <year>2023</year>
        <fpage>368</fpage>
        <lpage>373</lpage>
        <pub-id pub-id-type="pmid">36507870</pub-id>
      </element-citation>
    </ref>
    <ref id="bib14">
      <label>14</label>
      <element-citation publication-type="journal" id="sref14">
        <person-group person-group-type="author">
          <name>
            <surname>Chandrashekar</surname>
            <given-names>D.S.</given-names>
          </name>
          <name>
            <surname>Karthikeyan</surname>
            <given-names>S.K.</given-names>
          </name>
          <name>
            <surname>Korla</surname>
            <given-names>P.K.</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Shovon</surname>
            <given-names>A.R.</given-names>
          </name>
          <name>
            <surname>Athar</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>UALCAN: an update to the integrated cancer data analysis platform</article-title>
        <source>Neoplasia</source>
        <volume>25</volume>
        <year>2022</year>
        <fpage>18</fpage>
        <lpage>27</lpage>
        <pub-id pub-id-type="pmid">35078134</pub-id>
      </element-citation>
    </ref>
    <ref id="bib15">
      <label>15</label>
      <element-citation publication-type="journal" id="sref15">
        <person-group person-group-type="author">
          <name>
            <surname>Vasaikar</surname>
            <given-names>S.V.</given-names>
          </name>
          <name>
            <surname>Straub</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B.</given-names>
          </name>
        </person-group>
        <article-title>LinkedOmics: analyzing multi-omics data within and across 32 cancer types</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>46</volume>
        <year>2018</year>
        <fpage>D956</fpage>
        <lpage>D963</lpage>
        <pub-id pub-id-type="pmid">29136207</pub-id>
      </element-citation>
    </ref>
    <ref id="bib16">
      <label>16</label>
      <element-citation publication-type="journal" id="sref16">
        <person-group person-group-type="author">
          <name>
            <surname>Edwards</surname>
            <given-names>N.J.</given-names>
          </name>
          <name>
            <surname>Oberti</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Thangudu</surname>
            <given-names>R.R.</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>McGarvey</surname>
            <given-names>P.B.</given-names>
          </name>
          <name>
            <surname>Jacob</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The CPTAC data portal: a resource for cancer proteomics research</article-title>
        <source>J. Proteome Res.</source>
        <volume>14</volume>
        <year>2015</year>
        <fpage>2707</fpage>
        <lpage>2713</lpage>
        <pub-id pub-id-type="pmid">25873244</pub-id>
      </element-citation>
    </ref>
    <ref id="bib17">
      <label>17</label>
      <element-citation publication-type="journal" id="sref17">
        <person-group person-group-type="author">
          <name>
            <surname>Rudnick</surname>
            <given-names>P.A.</given-names>
          </name>
          <name>
            <surname>Markey</surname>
            <given-names>S.P.</given-names>
          </name>
          <name>
            <surname>Roth</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mirokhin</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Tchekhovskoi</surname>
            <given-names>D.V.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A description of the clinical proteomic tumor analysis consortium (CPTAC) common data analysis pipeline</article-title>
        <source>J. Proteome Res.</source>
        <volume>15</volume>
        <year>2016</year>
        <fpage>1023</fpage>
        <lpage>1032</lpage>
        <pub-id pub-id-type="pmid">26860878</pub-id>
      </element-citation>
    </ref>
    <ref id="bib18">
      <label>18</label>
      <element-citation publication-type="journal" id="sref18">
        <person-group person-group-type="author">
          <name>
            <surname>Ritchie</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Phipson</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Law</surname>
            <given-names>C.W.</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>43</volume>
        <year>2015</year>
        <fpage>e47</fpage>
        <pub-id pub-id-type="pmid">25605792</pub-id>
      </element-citation>
    </ref>
    <ref id="bib19">
      <label>19</label>
      <element-citation publication-type="journal" id="sref19">
        <person-group person-group-type="author">
          <name>
            <surname>Buccitelli</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Selbach</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>mRNAs, proteins and the emerging principles of gene expression control</article-title>
        <source>Nat. Rev. Genet.</source>
        <volume>21</volume>
        <year>2020</year>
        <fpage>630</fpage>
        <lpage>644</lpage>
        <pub-id pub-id-type="pmid">32709985</pub-id>
      </element-citation>
    </ref>
    <ref id="bib20">
      <label>20</label>
      <element-citation publication-type="journal" id="sref20">
        <person-group person-group-type="author">
          <name>
            <surname>Subramanian</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Tamayo</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Mootha</surname>
            <given-names>V.K.</given-names>
          </name>
          <name>
            <surname>Mukherjee</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ebert</surname>
            <given-names>B.L.</given-names>
          </name>
          <name>
            <surname>Gillette</surname>
            <given-names>M.A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>
        <source>Proc. Natl. Acad. Sci. U. S. A.</source>
        <volume>102</volume>
        <year>2005</year>
        <fpage>15545</fpage>
        <lpage>15550</lpage>
        <pub-id pub-id-type="pmid">16199517</pub-id>
      </element-citation>
    </ref>
    <ref id="bib21">
      <label>21</label>
      <element-citation publication-type="journal" id="sref21">
        <person-group person-group-type="author">
          <name>
            <surname>Tipney</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Hunter</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>An introduction to effective use of enrichment analysis software</article-title>
        <source>Hum. Genomics</source>
        <volume>4</volume>
        <year>2010</year>
        <fpage>202</fpage>
        <lpage>206</lpage>
        <pub-id pub-id-type="pmid">20368141</pub-id>
      </element-citation>
    </ref>
    <ref id="bib22">
      <label>22</label>
      <element-citation publication-type="journal" id="sref22">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>clusterProfiler 4.0: a universal enrichment tool for interpreting omics data</article-title>
        <source>Innovation (Camb.)</source>
        <volume>2</volume>
        <year>2021</year>
        <object-id pub-id-type="publisher-id">100141</object-id>
      </element-citation>
    </ref>
    <ref id="bib23">
      <label>23</label>
      <element-citation publication-type="journal" id="sref23">
        <person-group person-group-type="author">
          <name>
            <surname>Ashburner</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ball</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Blake</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Botstein</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Butler</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Cherry</surname>
            <given-names>J.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene ontology: tool for the unification of biology. The Gene Ontology Consortium</article-title>
        <source>Nat. Genet.</source>
        <volume>25</volume>
        <year>2000</year>
        <fpage>25</fpage>
        <lpage>29</lpage>
        <pub-id pub-id-type="pmid">10802651</pub-id>
      </element-citation>
    </ref>
    <ref id="bib24">
      <label>24</label>
      <element-citation publication-type="journal" id="sref24">
        <person-group person-group-type="author">
          <name>
            <surname>Gene Ontology</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>The gene ontology resource: enriching a GOld mine</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>49</volume>
        <year>2021</year>
        <fpage>D325</fpage>
        <lpage>D334</lpage>
        <pub-id pub-id-type="pmid">33290552</pub-id>
      </element-citation>
    </ref>
    <ref id="bib25">
      <label>25</label>
      <element-citation publication-type="journal" id="sref25">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Goto</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>28</volume>
        <year>2000</year>
        <fpage>27</fpage>
        <lpage>30</lpage>
        <pub-id pub-id-type="pmid">10592173</pub-id>
      </element-citation>
    </ref>
    <ref id="bib26">
      <label>26</label>
      <element-citation publication-type="journal" id="sref26">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Furumichi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Tanabe</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Morishima</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>45</volume>
        <year>2017</year>
        <fpage>D353</fpage>
        <lpage>D361</lpage>
        <pub-id pub-id-type="pmid">27899662</pub-id>
      </element-citation>
    </ref>
    <ref id="bib27">
      <label>27</label>
      <element-citation publication-type="journal" id="sref27">
        <person-group person-group-type="author">
          <name>
            <surname>Szklarczyk</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Gable</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Nastou</surname>
            <given-names>K.C.</given-names>
          </name>
          <name>
            <surname>Lyon</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Kirsch</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Pyysalo</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>49</volume>
        <year>2021</year>
        <fpage>D605</fpage>
        <lpage>D612</lpage>
        <pub-id pub-id-type="pmid">33237311</pub-id>
      </element-citation>
    </ref>
    <ref id="bib28">
      <label>28</label>
      <element-citation publication-type="journal" id="sref28">
        <person-group person-group-type="author">
          <name>
            <surname>Petralia</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Tignor</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Reva</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Koptyra</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Chowdhury</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Rykunov</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated proteogenomic characterization across major histological types of pediatric brain cancer</article-title>
        <source>Cell</source>
        <volume>183</volume>
        <year>2020</year>
        <fpage>1962</fpage>
        <lpage>1985.e31</lpage>
        <pub-id pub-id-type="pmid">33242424</pub-id>
      </element-citation>
    </ref>
    <ref id="bib29">
      <label>29</label>
      <element-citation publication-type="journal" id="sref29">
        <person-group person-group-type="author">
          <name>
            <surname>Arshad</surname>
            <given-names>O.A.</given-names>
          </name>
          <name>
            <surname>Danna</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Petyuk</surname>
            <given-names>V.A.</given-names>
          </name>
          <name>
            <surname>Piehowski</surname>
            <given-names>P.D.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Rodland</surname>
            <given-names>K.D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>An integrative analysis of tumor proteomic and phosphoproteomic profiles to examine the relationships between kinase activity and phosphorylation</article-title>
        <source>Mol. Cell. Proteomics</source>
        <volume>18</volume>
        <year>2019</year>
        <fpage>S26</fpage>
        <lpage>S36</lpage>
        <pub-id pub-id-type="pmid">31227600</pub-id>
      </element-citation>
    </ref>
    <ref id="bib30">
      <label>30</label>
      <element-citation publication-type="journal" id="sref30">
        <person-group person-group-type="author">
          <name>
            <surname>Hornbeck</surname>
            <given-names>P.V.</given-names>
          </name>
          <name>
            <surname>Kornhauser</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Tkachev</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Skrzypek</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>40</volume>
        <year>2012</year>
        <fpage>D261</fpage>
        <lpage>D270</lpage>
        <pub-id pub-id-type="pmid">22135298</pub-id>
      </element-citation>
    </ref>
    <ref id="bib31">
      <label>31</label>
      <element-citation publication-type="journal" id="sref31">
        <person-group person-group-type="author">
          <name>
            <surname>Linding</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>L.J.</given-names>
          </name>
          <name>
            <surname>Ostheimer</surname>
            <given-names>G.J.</given-names>
          </name>
          <name>
            <surname>van Vugt</surname>
            <given-names>M.A.T.M.</given-names>
          </name>
          <name>
            <surname>Jørgensen</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Miron</surname>
            <given-names>I.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Systematic discovery of in vivo phosphorylation networks</article-title>
        <source>Cell</source>
        <volume>129</volume>
        <year>2007</year>
        <fpage>1415</fpage>
        <lpage>1426</lpage>
        <pub-id pub-id-type="pmid">17570479</pub-id>
      </element-citation>
    </ref>
    <ref id="bib32">
      <label>32</label>
      <element-citation publication-type="journal" id="sref32">
        <person-group person-group-type="author">
          <name>
            <surname>Wiredja</surname>
            <given-names>D.D.</given-names>
          </name>
          <name>
            <surname>Koyuturk</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Chance</surname>
            <given-names>M.R.</given-names>
          </name>
        </person-group>
        <article-title>The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics</article-title>
        <source>Bioinformatics</source>
        <volume>33</volume>
        <year>2017</year>
        <fpage>3489</fpage>
        <lpage>3491</lpage>
        <pub-id pub-id-type="pmid">28655153</pub-id>
      </element-citation>
    </ref>
    <ref id="bib33">
      <label>33</label>
      <element-citation publication-type="journal" id="sref33">
        <person-group person-group-type="author">
          <name>
            <surname>Hutcheson</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Balaji</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Porembka</surname>
            <given-names>M.R.</given-names>
          </name>
          <name>
            <surname>Wachsmann</surname>
            <given-names>M.B.</given-names>
          </name>
          <name>
            <surname>McCue</surname>
            <given-names>P.A.</given-names>
          </name>
          <name>
            <surname>Knudsen</surname>
            <given-names>E.S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Immunologic and metabolic features of pancreatic ductal adenocarcinoma define prognostic subtypes of disease</article-title>
        <source>Clin. Cancer Res.</source>
        <volume>22</volume>
        <year>2016</year>
        <fpage>3606</fpage>
        <lpage>3617</lpage>
        <pub-id pub-id-type="pmid">26858311</pub-id>
      </element-citation>
    </ref>
    <ref id="bib34">
      <label>34</label>
      <element-citation publication-type="journal" id="sref34">
        <person-group person-group-type="author">
          <name>
            <surname>Payen</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Oberstein</surname>
            <given-names>P.E.</given-names>
          </name>
          <name>
            <surname>Saharkhiz</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Palermo</surname>
            <given-names>C.F.</given-names>
          </name>
          <name>
            <surname>Sastra</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Harmonic motion imaging of pancreatic tumor stiffness indicates disease state and treatment response</article-title>
        <source>Clin. Cancer Res.</source>
        <volume>26</volume>
        <year>2020</year>
        <fpage>1297</fpage>
        <lpage>1308</lpage>
        <pub-id pub-id-type="pmid">31831559</pub-id>
      </element-citation>
    </ref>
    <ref id="bib35">
      <label>35</label>
      <element-citation publication-type="journal" id="sref35">
        <person-group person-group-type="author">
          <name>
            <surname>Lai</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Cox</surname>
            <given-names>C.D.</given-names>
          </name>
          <name>
            <surname>Chandra Sekar</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Thurgood</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Jaworowski</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Peter</surname>
            <given-names>K.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mechanosensing by Piezo1 and its implications for physiology and various pathologies</article-title>
        <source>Biol. Rev. Camb. Philos. Soc.</source>
        <volume>97</volume>
        <year>2022</year>
        <fpage>604</fpage>
        <lpage>614</lpage>
        <pub-id pub-id-type="pmid">34781417</pub-id>
      </element-citation>
    </ref>
    <ref id="bib36">
      <label>36</label>
      <element-citation publication-type="journal" id="sref36">
        <person-group person-group-type="author">
          <name>
            <surname>Fang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Che</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lei</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF-kappaB/IL8 pathway</article-title>
        <source>Cell Death Discov.</source>
        <volume>7</volume>
        <year>2021</year>
        <fpage>32</fpage>
        <pub-id pub-id-type="pmid">33574243</pub-id>
      </element-citation>
    </ref>
    <ref id="bib37">
      <label>37</label>
      <element-citation publication-type="journal" id="sref37">
        <person-group person-group-type="author">
          <name>
            <surname>Sudol</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management</article-title>
        <source>Oncogene</source>
        <volume>30</volume>
        <year>2011</year>
        <fpage>3003</fpage>
        <lpage>3010</lpage>
        <pub-id pub-id-type="pmid">21383693</pub-id>
      </element-citation>
    </ref>
    <ref id="bib38">
      <label>38</label>
      <element-citation publication-type="journal" id="sref38">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Q.S.</given-names>
          </name>
          <name>
            <surname>Bode</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>T.S.</given-names>
          </name>
        </person-group>
        <article-title>Targeting CDK1 in cancer: mechanisms and implications</article-title>
        <source>NPJ Precis. Oncol.</source>
        <volume>7</volume>
        <year>2023</year>
        <fpage>58</fpage>
        <pub-id pub-id-type="pmid">37311884</pub-id>
      </element-citation>
    </ref>
    <ref id="bib39">
      <label>39</label>
      <element-citation publication-type="journal" id="sref39">
        <person-group person-group-type="author">
          <name>
            <surname>Fortelny</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Overall</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Pavlidis</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Freue</surname>
            <given-names>G.V.C.</given-names>
          </name>
        </person-group>
        <article-title>Can we predict protein from mRNA levels?</article-title>
        <source>Nature</source>
        <volume>547</volume>
        <year>2017</year>
        <fpage>E19</fpage>
        <lpage>E20</lpage>
        <pub-id pub-id-type="pmid">28748932</pub-id>
      </element-citation>
    </ref>
    <ref id="bib40">
      <label>40</label>
      <element-citation publication-type="journal" id="sref40">
        <person-group person-group-type="author">
          <name>
            <surname>Franks</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Airoldi</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Slavov</surname>
            <given-names>N.</given-names>
          </name>
        </person-group>
        <article-title>Post-transcriptional regulation across human tissues</article-title>
        <source>PLoS Comput. Biol.</source>
        <volume>13</volume>
        <year>2017</year>
        <object-id pub-id-type="publisher-id">e1005535</object-id>
      </element-citation>
    </ref>
    <ref id="bib41">
      <label>41</label>
      <element-citation publication-type="journal" id="sref41">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Jian</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A quantitative proteome map of the human body</article-title>
        <source>Cell</source>
        <volume>183</volume>
        <year>2020</year>
        <fpage>269</fpage>
        <lpage>283.e19</lpage>
        <pub-id pub-id-type="pmid">32916130</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="appsec1" sec-type="supplementary-material">
    <title>Supplemental Data</title>
    <p id="p0200">
      <supplementary-material content-type="local-data" id="mmc1">
        <caption>
          <title>Supplemental Tables S1–S4</title>
        </caption>
        <media xlink:href="mmc1.xlsx"/>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ack0010">
    <title>Acknowledgments</title>
    <p id="p0205">This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100012166</institution-id><institution>National Key R&amp;D Program of China</institution></institution-wrap></funding-source> (2021YFA1101000 and 2022YFA1105200), the <funding-source id="gs2">Chinese National Natural Science Funds</funding-source> (U20A20393, 32270975, 32070907, 92169122, 82371841, 32100699, 31771619, 32200575, and 22074132), the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100014219</institution-id><institution>National Science Fund for Distinguished Young Scholars</institution></institution-wrap></funding-source> (32125016 and 31925013), the <funding-source id="gs4">China National Postdoctoral Program for Innovative Talents</funding-source> (BX2021208), the <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source> (2021M692350) and <funding-source id="gs6">Suzhou Innovation and Entrepreneurship Leading Talent Program</funding-source> (ZXL2022505, ZXL2022442, and ZXL2023206), Key Cross-Research Projects of the School of Medicine, <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100022956</institution-id><institution>Soochow University</institution></institution-wrap></funding-source> (YXY2303027), and the <funding-source id="gs8">Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases</funding-source>. Additionally, we acknowledge the support from the <funding-source id="gs9">Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases</funding-source>，the platform of the <funding-source id="gs10">Zhejiang University School of Medicine</funding-source> and the <funding-source id="gs11">Life Sciences Institute</funding-source>.</p>
    <sec id="sec6">
      <title>Author contributions</title>
      <p id="p0195">J. Z., Z. Q., and R. L., methodology; J. Z. and Z. Q. writing-original draft; J. Z. software; Z. Q. visualization; X. Y., H. H., B. Y., F. Z., and L. Z. conceptualization; X. Y., H. H., F. Z., and L. Z. writing–review and editing.</p>
    </sec>
  </ack>
</back>
